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ABSTRACT 
 
La nefrolitiasi calcica idiopatica (NCI) è una malattia multifattoriale, la cui patogenesi 
dipende dall’interazione di fattori ambientali, metabolici, anatomici e genetici. 
L’importanza dei fattori ereditari è emersa da diversi studi su famiglie e gemelli affetti da 
NCI. Il modello di ereditarietà più probabile sembrerebbe, come predetto da programmi 
bioinformatica, ad eredità monogenica co-dominante o poligenica. 
La maggior parte degli studi a gene candidato o di associazione condotti fin ora ha prodotto 
risultati negativi o marginali, lasciando pertanto le basi genetiche della NCI una questione 
ancora aperta. 
Tuttavia, le nuove tecnologie di analisi genetica sono in continua evoluzione e potrebbero 
contribuire ad approfondire le nostre conoscenze sulla patogenesi della NCI.  
Le tecnologie whole-genome scanning, quali Next-Generation Sequencing (NGS) and CGH 
(Comparative Genomic Hybridization)  array, rappresentano gli approcci di genetica 
molecolare più recenti, e permettono di tracciare una mappa completa della variabilità 
presente nel genoma umano, in particolare SNPs (Single Nucleotide Polymorphisms) e 
varianti strutturali. Negli ultimi anni l’importanza di queste ultime, maggiormente 
rappresentate dalle Copy-Number Variants (CNVs),  è stata infatti dimostrata in numerosi 
studi che ne hanno individuato un ruolo critico per lo sviluppo di malattie genetiche 
complesse. 
 
Scopo di questo studio è stata la ricerca di alcune delle maggiori varianti di suscettibilità 
alla NCI, applicando l’enorme potenziale delle tecnologie whole genome scanning ad un 
caso studio molto peculiare, sia per manifestazioni cliniche che per il bagkground genetico. 
Il probando da circa 30 anni è affetto da una forma severa di NCI, con ipercalciuria 
intermittente e tubulopatia fosfaturica, espellendo fino ad oggi circa 300 calcoli, sia 
spontaneamente che mediante litotripsia (33 interventi). Egli appartiene ad una famiglia con 
consanguineità, in cui la nefrolitiasi viene trasmessa in modo apparentemente dominante, 
con maschi affetti più severamente e meno frequentemente rispetto alle femmine. 
Da un’analisi CGH array, al fine di individuare la presenza di eventuali CNV, è stato 
possibile identificare una duplicazione di una regione di 308 Kb del cromosoma X (Xq22.2 
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CNV) del probando. Questa CNV è risultata particolarmente interessante poiché fin ora mai 
identificata e condivisa da altri tre familiari  (eredità materna). 
Inoltre, confrontando la duplicazione Xq22.2 con un database di 14375 individui sono state 
identificate solo 5 duplicazioni “ overlappanti”, confermandone pertanto l’estrema rarità. In 
particolare, tutte queste 5 duplicazioni mostravano una regione minima comune, 
corrispondente al gene NUP62CL, suggerendone una possibile significatività. In uno studio 
di espressione da noi effettuato si è inoltre osservata una significativa e marcata down-
regolazione di NUP62CL. Pertanto, pur non avendone avuto prova definitiva, è sembrato 
che la CNV Xq22.2  giocasse un ruolo importante nella patogenesi della NCI nella nostra 
famiglia. Tuttavia, data la sua presenza anche in un membro non evidentemente affetto e 
considerata anche la severità del fenotipo NCI di  alcuni membri del ramo paterno, è stato 
ipotizzato che la presenza aggiuntiva di altri determinanti genetici potesse essere 
responsabile del fenotipo estremo riscontrato nel probando. In quest’ottica,  è stato 
sequenziato l’intero esoma del probando (Whole Exome Sequencing) al fine di individuare 
varianti puntiformi rare che potessero agire da ulteriori varianti di suscettibilità alla NCI 
nella famiglia caso studio. 
La fase di analisi bioinformatica e validazione molecolare ha portato a delineare un quadro 
di eredità poligenica, con l’individuazione di quattro possibili geni di suscettibilità: XDH, 
ATP6V1B1, HNF1B, NUP62CL. Il gene XDH, fattore causativo della xanthinuria di tipo I, 
è stato evidenziato per la presenza di due varianti rare con un predetto effetto dannoso sulla 
struttura proteica. Il gene ATP6V1B1, di cui è già noto il ruolo nell’acidosi tubulare distale, 
presentava una variante missenso che sembrava render conto del fenotipo intermedio 
ipocitraturia osservato nella famiglia. E’ stata individuata, inoltre, una variante 
estremamente rara nel gene HNF1B, un fattore causativo di nefropatia cistica e, 
concordemente, il probando recentemente aveva mostrato la presenza di cisti pre-caliceali. 
Infine, soprendentemente, è stato possibile evidenziare ancora una volta il gene NUP62CL 
per la presenza di due varianti omozigoti, che agiscono attivando dei siti criptici di splicing 
e quindi con un probabile effetto di produzione di un mRNA aberrante. Questo gene non è 
stato mai associato alla NCI ma, possedendo un ruolo noto nel trasporto dell’ossalato, 
potrebbe essere responsabile di alcuni dei meccanismi che sottendono alla patogenesi della 
NCI.  
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 ABSTRACT 
 
Idiopathic calcium nephrolithiasis (ICN) is a multifactorial disease with a pathogenesis 
depending upon the interplay of environmental, metabolic, anatomical and genetic factors. 
The importance of hereditary factors in ICN has emerged from a number of studies on 
families and twins affected by ICN. Computer programs predicted the best inheritance fit 
with a model of single gene co-dominant model/polygenic model.  
Most candidate gene or association studies have produced, up to date, negative or only 
marginal results, leaving the genetic basis of ICN still an open question. But, genetic 
analysis techniques are rapidly evolving and promise to improve our knowledge of the 
genetic basis of nephrolithiasis and allied disorders. 
Whole-genome scanning techniques, like Next-Generation Sequencing (NGS) and CGH 
(Comparative Genomic Hybridization) array, are the most recent technical approaches of 
molecular genetics that allow to trace out a complete draw of variation present in the 
human genome,  namely SNPs (Single Nucleotide Polymorphisms) and heterogeneous 
structural variants. In the last years, indeed, several studies have recognized the critical role 
of structural genetic variants, mostly represented by Copy-Number Variants (CNVs),  in 
modulating gene expression and complex diseases phenotype.  
 
Aim of this project was to identify some of the major susceptibility genes involved in 
idiopathic calcium nephrolithiasis applying the potential of whole-genome scanning 
technologies to a case study very peculiar, both for clinical manifestations both for its 
genetic background. 
The proband, since 30 years, suffers of a recurrent and severe form of ICN, with 
intermittent hypercalciuria and phosphaturic tubulopathy, expelling, up to date, about 300 
calculi both spontaneously and by lithotripsy (33 treatments). Strikingly, he belongs to a 
family with consanguinity in which nephrolithiasis is present in several members and is 
transmitted in an apparently dominant fashion, with males being more severely affected 
than females. 
CGH arrays has been performed in the proband and in eight members of the family in order 
to detect the presence of CNVs in the genome. A duplication of 308 kb region of the 
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Xq22.2 chromosome has been detected in the proband. This CNV resulted particularly 
interesting because it was a novel (not known) variant and it was shared by other three 
family members (maternal inheritance). 
Moreover, matching the Xq22.2 duplication over a database of 14375 individuals only 5 
overlapping duplications were found, confirming its extreme rarity. Strikingly, all these 5 
duplication shared a common region that corresponded to NUP62CL gene, suggesting a 
likely importance of this genetic trait. Furthermore, performing an expression study, we 
observed a significant and marked down-regulation of NUP62CL. 
Thus, even if we could not have a definitive proof of principle, this Xq22.2 CNV seemed to 
have an important role for ICN pathogenesis in our family. Nonetheless, given its presence 
in a member of the family that was not evidently affected and given the severity of the 
phenotype of some members of the paternal branch, we postulated that additional genetic 
determinants were also responsible of the severe phenotype encountered in the proband. In 
this light, we  performed whole exome sequencing of the proband to identify rare single 
nucleotide variants that may have a role as susceptibility variants for ICN in the case-study 
family. 
By bioinformatic analyses and molecular validation, we could draw a polygenic model of 
heredity, with the identification of four possible susceptibility genes: XDH, ATP6V1B1, 
HNF1B, NUP62CL. The XDH gene, normally responsible of xanthinuria type I, was 
highlighted for the presence of two very rare variants with a damaging predicted effect on 
protein. Next, we discovered a missense homozygous variant in ATP6V1B1 gene, whose 
role is already known in distal tubular acidosis, that seemed to account for the ICN 
intermediate phenotype hypocitraturia observed in the family. In addition, we found an 
extremely rare heterozygous variant in HNF1B gene,  a causative factor in cystic 
nephropathy, and the proband, indeed, recently showed pre-calyceal cysts. Strikingly, we 
again evidenced NUP62CL gene for the presence of two homozygous variants that operate 
activating criptic splicing sites, thus eventually generating an aberrant mRNA. This gene 
has never been associated to ICN but, having a known role in oxalate transport, could be 
responsible of some of the biological mechanisms that are on the basis of ICN 
pathogenesis. 
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1. INTRODUCTION 
 
 
1.1. NEPHROLITHIASIS 
 
Nephrolithiasis is a common disease, typically occurring between 30 and 60 years of age 
and it represents the most chronic kidney condition after hypertension. In the majority of 
patients the symptoms and consequences are not life threatening, but stones in the urinary 
tract are a major cause of morbidity, hospitalisation and days lost from work (Saigal et al., 
2005). In Italy for example, the number of patients receiving hospital treatment between 
1988 and 1993 increased from 60 to 80,000 per year; among these, 14% (12,000 
patients/year) required surgical treatment or urological manoeuvres and the number of 
extracorporeal shock wave lithotripsy sessions was approximately 50,000 per year 
(Gambaro et al., 2004).  
Initiation and growth of stones is determined by supersaturation of urine with respect to a 
solute (calcium, oxalate, uric acid and cystine), that leads to a phase change in which 
dissolved salts condense into solids  thus forming the stone. 
Nephrolithiasis and the metabolic characteristics of urinary stones are heterogeneous: there 
are many types of renal stones, but the most common are calcium-containing stones making 
up 75% of all stones. Calcium oxalate (CaOx) is the predominant component of most 
stones (Worchester and Coe, 2008), often admixed with some calcium phosphate (CaP), 
which may form the initial nidus of the stone.  
For CaOx stones, the most important determinants of urinary supersaturation are the total 
daily calcium excretion and urine volume, that is, the urine calcium concentration. In 
addition to solute concentration, urine pH constitutes a critically important determinant of 
solubility for CaP, uric acid and cystine (Coe et al., 2007). 
However, urinary CaOx supersaturation is found frequently in normal subjects and this 
occurs, most likely, because of the presence of crystallization inhibitors in urine (citrate, 
pyrpophopshate, as well as at least a dozen proteins - like osteopontin -  and 
glycosaminoglycans), which can impede the nucleation, growth, and aggregation of crystals 
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in vitro and have been shown experimentally to interfere with crystal attachment to renal 
epithelial cells (Kumar and Lieske, 2006). 
The initial presentation of nephrolithiasis occurs often with renal colic - severe pain caused 
by stone passage- triggered by movement of a stone from the renal pelvis into the ureter, 
which leads to ureteral spasm and possibly obstruction. A radiograph of the kidneys, ureters 
and bladder often can visualize calcium-containing stones in the kidney or ureter, including 
struvite stones, but uric acid, purine and cystine stones are often visualized poorly. Stones 
smaller than 5 mm in diameter usually can pass spontaneously, but about 50% of stones 
larger than 5 mm require urologic intervention for removal, and those larger than10 mm are 
very unlikely to pass unaided. 
Therapeutic attention has been directed more to the intervention on already formed stones, 
than to the prevention of stone formation, very often because the nature of stones is not 
threatened by any drug. There are several options of surgical treatment for the 10% to 20% 
of stones that fail to pass spontaneously (Auge and Preminger, 2002), and the appropriate 
chose depends on the size, the location, and the type of stone, or the presence of anatomic 
abnormalities or infections. Nevertheless every urologic treatment is made by invasive 
extra- and intra-corporeal manoeuvres. Extracorporeal shock wave lithotripsy (ESWL) uses 
sound waves to fragment stones into small pieces that can be passed easily, but is effective 
for most stones smaller than 2 cm and phosphate and cystine stones appears to be resistant 
to fragmentation. Larger stones can be removed by percutaneous lithotripsy, through a 
small flank incision that allows direct visualization, stone disruption and removal of 
fragments. 
It is clear that all these urologic measures have no effects over the incidence and worsening 
of nephrolithiasis, in some cases being even cause of new colic episodes due to the 
permanence of  stone fragments in the urinary tract (Fine et al, 1995), thus representing no 
ideal treatments of nephrolithiasis.  
Therefore, it appears more and more necessary to understand deeply basic metabolic-
physiologic mechanisms that are causative factors of nephrolithiasis pathogenesis and 
eventually develop new preventive and targeted therapies. 
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1.1.1. Renal pathology in stone formers 
 
Retention of crystals within the kidney is necessary for stone formation and it occurs  with 
several patterns of deposition in kidney of stone formers, and these patterns are associated 
with specific stone types. Patients who have idiopathic CaOx stones have white deposits on 
their papillae, called “Randall’s plaque” (Evan AP, Lingeman JE, Coe FL et al., 2003). 
Biopsies of these areas reveals interstitial deposits of CaP, in the form of biologic apatite, 
which starts in the basement membrane of the thin loops of Henle and contain layers of 
protein matrix. Deposits can extend down to the tip off the papilla, and if the overlying 
urothelium is denuded, the exposed plaque can become  an attachment site for stones (Evan 
P, Coe FL, Lingeman JE et al., 2007). Stones seem to start as deposits of amorphous CaP 
overlying the exposed plaque, interspersed with urinary proteins. With time, more layers of 
protein and mineral are deposited, and the mineral phase becomes predominantly CaOx 
(Fig. 1). 
 
   
 
Figure 1.  Concept of stone growing on Randall’s plaque (RP). 
A) The plaque appears in the interstitial tissue within the renal papilla, 
with no crystals present in any tubular lumens. The plaque is composed 
of calcium phosphate in the mineral form of apatite. B) Papillary 
epithelium is lost, and the plaque is uncovered so that its surface is 
bathed with urine in the renal calyx. The resulting calcium oxalate stone 
may grow only very slowly, and can remain small for an extended 
period of time, as the plaque keeps the stone from flowing out with the 
urine, and the insolubility of the calcium oxalate makes the stone quite 
stable with time. The layers in the schematic represent hypothetical 
growth periods for the stone, periods which could be separated by 
weeks or even months. C) Some stones that are formed on Randall’s 
plaques are released from the papilla in which they formed, by a process 
that is not known 
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By contrast, in patients with stone constitution mainly of CaP (apatite or brushite) stones 
are not attached to plaque. Instead, many collecting ducts are filled with crystal deposits 
made of apatite that fill the tubule lumen and may protrude from the mouths of the ducts of 
Bellini. Overall, most stone formers studied so far have crystal deposits in the medullary 
collecting ducts, except for those who have idiopathic CaOx stones, that have no 
intratubular deposits but instead have abundant deposits of apatite in the papillary 
interstitium. 
Strikingly, if the manifestation of urinary stones is due to multiple different underlying 
pathologies, then studying patients grouped together simply under the category of “stone 
former” will certainly result in confusion. Even specifying patients under the term “calcium 
stone former” can lump together pathologies that appear to be completely separated in 
primary cause of the disease.  
In conclusion, it appears necessary to integrate pathology mechanisms in the general 
picture of every stone former patient, thus enabling to define a clearer phenotype that 
results essential to further basic biology and genetic studies. 
 
 
    
1.1.2. Risk factors  
 
Environmental factors, especially diet, play an important role in expression of the tendency 
of stone formation. Evidence of environmental influence includes the different distribution 
of the disease in wealthier as opposed to poorer areas, its constant increase in industrialized 
countries during the last century (an increase only temporarily interrupted by World Wars I 
and II), and the recently reported increasing prevalence of nephrolithiasis in younger 
women (Robertson et al., 1999). The reasons for increasing prevalence are not clear but, for 
instance, mass index and waist circumference seem to play a role, especially in women 
(Taylor et al., 2005).  
However, also inherited factors play a role in stone formation. In fact, under the same 
environmental conditions, only a few individuals tend to develop stone disease (incidence 
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estimated at 1%/y; prevalence, ≥10%), and these subjects frequently have family 
members affected by the disease.  
Nephrolithiasis, indeed, occurs more frequently in individuals with a positive family history 
of renal stones. Large-scale epidemiological surveys have shown a familial aggregation for 
kidney stones, with a greater risk for first-degree relatives (McGeown, 1960; Resnick et al., 
1968; Robertson et al., 1983). 
For example, as regards patients with idiopathic calcium nephrolithiasis, 16 to 50% of have 
a positive family history of nephrolithiasis (Mehes and Szelid, 1980; Coe et al., 1979). In 
the United States, a family history of nephrolithiasis was reported in 16% and 17% of stone 
patients by Resnick et al (1968) and Curhan et al. (1997), respectively. A much greater 
prevalence has been observed in Italy. Trinchieri et al. (1988) observed a familial 
aggregation in 37% of cases, and we reported that as many as 38% of non-recurrent and 
50% of recurrent stone formers have a positive family history of nephrolithiasis (Gambaro 
et al., 1996). In 71 Canadian families from a genetically and geographically homogeneous 
population, hypercalciuria segregates with stone formation (Tessier et al., 2001). 
The importance of hereditary factors in idiopathic calcium nephrolithiasis has emerged 
from a number of studies of families containing members affected by renal stone disease 
and from twin studies. Computer programs predicted the best inheritance fits with a model 
of single gene co-dominant model/polygenic model. Both models gave a heritability scores 
of 58%. As a whole, genes might determine over 50% of the urinary calcium excretion rate. 
The role of inheritance is clearest in the monogenic forms of nephrolithiasis such as 
cystinuria, Dent’s disease, and primary hyperoxaluria (Coe et al., 2005). There is a clear 
familial tendency in idiopathic stone formation as well (Goldfarb et al., 2005), although the 
genes involved are currently unknown. 
In the last decade important additions have been made to our knowledge by Bushinsky’s 
animal model (Bushinsky, 1999), the important theoretical contribution from Goodman et 
al. (Goodman et al., 1995) on idiopathic calcium nephrolithiasis as a polygenic disorder, 
and the studies of Canadian stone-former sib-ships by the Bonnardeaux group (Scott et al., 
1998). 
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1.1.3. Idiopathic Calcium Nephrolithiasis 
 
Calcium stones are the most common in idiopathic calcium nephrolithiasis (ICN), and they 
are associated with a number of metabolic derangements, the most common is 
hypercalciuria. Elevate urine calcium excretion, indeed,  is the most common abnormality 
found in both adults and children who form kidney stones: 30% to 60% of adult and 
paediatric stone formers have hypercalciuria. Many monogenic diseases are associated with 
hypercalciuria, but the majority of cases in stone formers are caused by either idiopathic 
hypercalciuria (IH) or primary hyperparathyroidism (PHPT). 
The term “idiopathic hypercalciuria” is generally applied to cases in which serum calcium 
is normal and other causes of increased calcium excretion, such as vitamin D excess, renal 
tubular acidosis, granulomatous disease such as sarcoid, steroid use and hyperthyroidism 
have been excluded. 
IH can involve normally calcium handling by gut, kidney and bone. Patients with IH very 
often have elevated serum 1,25.dihydroxy vitamin D levels and increased intestinal calcium 
adsorption (Coe et al., 2004) . Their kidneys exhibit a decreased ability to reabsorb filtered 
calcium. A decreased renal reabsorption of phosphate may also occur, and serum phosphate 
levels are low in patients with IH.  
For idiopathic hypercalciuric who have recurrent stones, thiazide diuretics, which can lower 
urine calcium, are the treatment of choice (Borghi et al., 1993). 
Low urinary citrate excretion may occur in a large fraction of stone formers as a 
consequence of acidosis or potassium depletion or in case of an idiopathic disorder; it is 
frequently associated with other metabolic disorders that increase stone risk. Citrate can 
inhibit stone formation for its ability to chelate calcium, forming a soluble complex that 
prevents calcium binding with oxalate or phosphate. In addition, citrate can act on the 
surface of preformed  CaOX or CaP crystals as  a growth inhibitor. 
Citrate has also been used as a treatment for idiopathic calcium stone formers, especially in 
those who have low urine citrate levels (Barcelo et al., 1993). 
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Hyperoxaluria is a quite common metabolic condition among stone formers and, apart from 
genetic primary hyperoxaluria, may be caused by increased oxalate absorption triggered by 
a low calcium diet (Asplin, 2002). 
Patients who forms CaOx stones may have also elevetaed uric acid excretion, and 
hyperuricosuria decreases solubility of CaOx and promotes stones. Patients who have 
hyperuricosuric calcium stones differ from patients who have gout and uric acid stones 
because they have higher urine pH and a higher urine uric acid level as well. 
Most calcium stones are composed predominantly of CaOx with small amounts of 
admixted CaP. Normally, stones containing more than 50% CaP are uncommon and form 
when urinary CaP supersaturation is persistently elevated. The major determinants of CaP 
supersaturation are alkaline urine (pH>6.3) combined with hypercalciuria (Parks et al., 
2004). This condition is seen in patients who have distal renal  tubular acidosis, whether 
genetic or acquired, but most patients who have CaP stones do not have metabolic acidosis, 
and the cause of their persistently alkaline pH is unclear. 
 
 
 
 
1.1.4. Genetics of idiopathic calcium nephrolithiasis 
 
During the past years it appeared more and more clearly that genetic factors are important 
determinants of the individual’s risk of developing kidney stones. As many as 40% of 
hypercalciuric stone formers have at least one first-degree relative with nephrolithiasis 
(Pak, 1979). Men form stones three times more than women, and men with kidney stones 
are three time more likely to have a parent or sibling with a history of kidney stones 
(Curhan et al., 1997). This  indicates that, although as previously discussed shared dietary 
or environmental   factors may contribute, the principal determinants for these associations 
are probably genetic in origin. 
Nevertheless, the genetics of ICN is very often complicated by  a number of issues. 
Primarily, some patients may inherit a predisposition  to an abnormality, but the 
abnormality itself may not be manifest at all times. This can therefore make it very difficult 
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to assign phenotype properly when conducting family studies and it obligates to make 
observations under standardized conditions. A second complicating issue is  that many 
patients form stones in the setting of several metabolic abnormalities. Thus, for example, a 
particular patient with calcium stones may have hypercalciuria, hyperoxaluria, and 
hypocitraturia, whereas other members of the family may share some but not all of the 
same risk factors. 
A third complicating issue is that, with the exception of rare monogenic diseases, some risk 
factors for stones may reflect not a single gene but rather the interacting effects of multiple 
genes. 
Idiopathic hypercalciuria, indeed, occurs 40% or more  in patients that have a family 
history of nephrolithiasis. Eventhough several studies have presented families  in which 
hypercalciuria appears to be inherited as an autosomal trait (Coe et al., 1979; Mehes et al., 
1980), there are several reasons to conclude that hypercalciuria is not a monogenic but 
rather a quantitative trait. 
In the nineties, studies of gene mapping and positional cloning  have identified a candidate 
gene for hypercalciuria, CLC-5 chloride channel, that is mutated in X-linked nephrolithiasis 
or Dent’s disease, characterized generally by LMW ( low molecular weight) proteinuria, 
low level of parathyroid hormone (PTH), and hypercalciuria, and very often by 
nephrocalcinosis and nephrolithiasis. 
CLC-Kb, another channel of chloride channel family and ROMK (KCNJ1), a potassium 
voltage gated channel, have been already identified as responsible of Bartter syndrome, 
another hypercalciuric condition (Simon DB et al., 1997).  
From a number of candidate gene, association and linkage studies, it has been demonstrated 
that polymorphisms in a variable number of candidate genes could be associated with 
higher calcium excretion and/or nephrolithiasis, among them VDR and CaSR genes (Pearce 
et al., 1996; Scott et al., 1999) (Table1).  
Nevertheless, with the expanding scenario of novel molecular genetic techniques, it is 
reasonable to expect exciting advances in our understanding  of the genetics of ICN. 
 
 
 
17 
 
 
 
 
 
 
Table 1. Genetic defects related to monogenic forms renal stone disease associated or not associated to  
hypercalciuria (Image by Stechman et al., 2009). 
 
 
 
 
 
1.2 MOLECULAR GENETICS: COMPLEXITY OF HUMAN 
GENOME AND COMPLEX GENETIC DISEASES. 
 
The approach to molecular genetic studies of complex diseases evolved considerably 
during the recent years. In particular the candidate gene approach, restricted normally to an 
analysis of a few single-nucleotide polymorphisms, has been supplanted by the unbiased 
approach of genome-wide studies that exploit the enormous potential of whole-genome 
Not associated with hypercalciuria 
Associated with hypercalciuria  
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scanning techniques. To better understand the extreme complexity of human genetics and 
complex genetic diseases and the fine relationship that exists between them, it is firstly  
necessary to clarify some new genetic concepts. Whole genome scanning techniques, 
indeed, revealed extreme variability in humans and allowed to discover new forms of 
genetic variation 
 
 
 
1.2.1 Single-Nucleotide Polymorphims 
 
A single-nucleotide polymorphism (SNP) is a DNA sequence variation occurring when a 
single nucleotide — A, T, C or G — in the genome differs between members of a 
biological species or paired chromosomes in a human. 
Humans are genetically diverse and they differ in approximately 0.1% of their genomes. 
The single-nucleotide polymorphism database (dbSNP) lists more than 37 million variants 
among humans. With the exception of identical twins, no two humans have identical 
genomes. Every genome contains approximately 4 million of DNA sequence variants 
(DSVs) that affect half of the genes in each genome collectively, and many are private 
(Pennisi E, 2010; Wheeler et al., 2008).  
Among the approximately 3.5 million SNPs in each genome, approximately 10,000 SNPs 
are nonsynonymous SNPs (nsSNPs), of which approximately two thirds are predicted by in 
silico analysis to impart potentially damaging effects. In addition, each genome contains 
approximately 50 to 100 variants that have been associated with inherited disorders and 
approximately 30 de novo variants, whose presence is indicative of continuous introduction 
of new variants to the genetic pool (Durbin et al., 2010). 
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1.2.2 Structural variations 
 
Most DSVs in the genome are SNPs, but a big portion of variants is constituted by 
structural variations (SVs). They affect more nucleotides in the genome, simply because of 
their sizes and the first identified were small deletions, insertions and duplications (<1kb). 
Genome-scanning array technologies and comparative DNA-sequence analyses have begun 
to reveal DNA variations that involve segments that are smaller than those recognized 
microscopically (e.g. aneuploidies, chromosomal rearrangements, heteromorphisms, fragile 
sites) but larger than those that are readily detected by conventional sequence analysis (e.g. 
SNPs, micro- and mini-satellites) . These variants, which range from ~1 kb to 3 Mb in size, 
are normally refererred as submicroscopic structural variants. 
In the last decade rearrangements of larger segments of DNA (>1 kb) were discovered 
through CGH (Comparative Genomic Hybridization) array technology, with the 
contemporary understanding that they might increase or decrease the copy number of the 
genes from the natural two copies (Mills RE et al., 2011; Eichler EE et al., 2010). Such SVs 
are referred to as Copy Number Variants (CNVs).  
 
 
 
 
1.2.2.1 Copy-Number Variants: meaning and identification techniques 
 
The DNA encodes around 23,500 genes. It was generally thought that genes were almost 
always present in two copies in a genome. However, recent discoveries have revealed that 
large segments of DNA, ranging in size from thousands to millions of DNA bases, can vary 
in copy-number. In particular, a Copy- Number Variants represents a segment of DNA that 
is 1 kb or larger and is present at variable copy number in comparison with a reference 
genome. Classes of CNVs include insertions, deletions and duplications. This definition 
also includes large-scale copy number variants, which are variants that involve segments of 
DNA ≥50 kb (LCV). 
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Such copy number variations can encompass genes leading to dosage imbalances. For 
example, genes that were thought to always occur in two copies per genome have now been 
found to sometimes be present in one, three, or more than three copies. In a few rare 
instances the genes are missing altogether (Fig. 2). Thus, the new findings seems to indicate 
that our DNA is less than 99.9% identical, as was previously thought. 
 
      
 
 
 
Studies over the past six years have resulted in increasing recognition of the critical role of 
structural genetic variation (most of which appear to be in the form of copy number 
variation) in modulating gene expression and disease phenotype. CNVs, indeed, are now 
known to be a prevalent form of common genetic variation and represent a substantial 
proportion of total genetic variability in human populations. 
Moreover, association studies have already demonstrated the importance of CNVs as 
disease-susceptibility variants, with specific CNVs found to confer differential risk to HIV 
infections, autoimmune disease, and asthma (Gonzalez et al., 2005; Fanciulli M et al.,  
2007; Brasch-Andersen C. et al., 2004). Recently, genome-wide surveys have  
demonstrated that rare CNVs altering genes in neurodevelopmental pathways are 
implicated in several neuropsychological disorders, like autism and schizophrenia (Sebat J, 
Figure 2. Copy number variation in the 
human genome. The 30,000 genes are usually 
present in two copies. A new map of the 
genome has been unveiled that catalogues 
DNA and genes variable in copy number 
(those numbers others that 2 are highlighted in 
red). Duplication of a gene (top) and deletion 
of two genes (bottom) are depicted. (Image by 
http://www.sickkids.ca/mediaroom/custom/gen
omevariation06.asp) 
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et al. 2007; Walsh T, et al., 2008). It is therefore becoming increasingly clear that genetic 
studies of complex diseases must pay closer attention to the contribution of CNVs. 
Several distinguishing features of CNVs support their role in disease pathogenesis. First, 
though less abundant than SNPs, it has been suggested that CNVs account for more 
nucleotide variation than do SNPs because of their size. By spanning thousands of bases, 
CNVs often encompass (and can sometimes disrupt) functional DNA sequences. Second, 
there appears to be an enrichment of currently-known CNVs toward “environmental 
sensor” genes – i.e. genes that are not necessarily critical for early embryonic development, 
but rather help us to perceive and interact successfully with our ever-changing environment  
(Sebat J et al., Science 2004). This includes enrichment for olfactory receptors, immune 
and inflammatory response genes, cell signaling and cell adhesion molecules, structural 
proteins, and ion channels. Third, a recent comparison of the relative impact of SNPs and 
CNVs on gene expression noted that a substantial proportion (~18%) of gene expression 
variability was attributable to known CNVs greater than ~40 kb in size (Stranger BE et al., 
2007). Lastly, like other forms of genetic variation, both purifying and adaptive natural 
selective pressures appear to have influenced the frequency distribution of selective CNVs, 
suggesting their functional significance (Redon R et al., 2006). 
 
Currently, the main approaches for identifying unbalanced structural variants are array- 
based analyses and quantitative primarily PCR-based assays. Array-based comparative 
genome hybridization (array-CGH) approaches (Pinkel D et al., 1998) provide the most 
robust methods for carrying out genome-wide scans to find novel CNVs. These approaches 
use labeled fragments from a genome of interest, which are competitively hybridized with a 
second differentially labeled genome to arrays that are spotted with cloned DNA fragments, 
revealing copy-number differences between the two genomes (Fig. 3). 
Nevertheless, the most robust assays for screening targeted regions of the genome are 
mainly PCR-based, whose the best established is real-time quantitative PCR (Bieche I et 
al., 1998). However, although most protocols for this method work well for detecting 
individual deletions and duplications, they are generally not suitable for multiplexing. 
Structural variants can also be identified in silico by comparing DNA sequences from 
different sources. In the simplest approach, two assemblies from unique human DNA 
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sources are aligned to detect differences (Tuzun et al, 2005). One advantage of this method 
is that all types of variant, including balanced variants, can be detected. In addition, there is 
no limit to the resolution, and the variants that are identified can be defined at the 
nucleotide level (Feuk et al., 2005) 
 
 
 
 
Figure  3. Array-CGH for the identification of copy-number variants. In array based comparative genome 
hybridization (array-CGH), reference and test DNA samples are differentially labeled with fluorescent tags 
(Cy5 and Cy3, respectively), and are then hybridized to genomic arrays after repetitive-element binding is 
blocked using COT-1 DNA. The array can be spotted with one of several DNA sources, including BAC 
clones, PCR fragments or oligonucleotides. After hybridization, the fluorescence ratio (Cy3:Cy5) is 
determined, which reveals copy-number differences between the two DNA samples. Typically, array-CGH is 
carried out using a ‘dye-swap’ method, in which the initial labelling of the reference and test DNA samples is 
reversed for a second hybridization (indicated by the left and right sides of the panel). This detects spurious 
signals for which the reciprocal ratio is not observed. (Image by Feuk et al., 2006) 
 
 
The current map of structural variation in the human genome is far from being complete. 
While several databases exist to catalog this newly-appreciated form of human genetic 
variation (notably the Database of Genomic Variants - http://projects.tcag.ca/variation/ and 
the Human Structural Variation database - 
http://humanparalogy.gs.washington.edu/structuralvariation/), quality control is lacking, 
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and studies have differed in technological approaches, precise boundary definition of 
CNVs, DNA quality, and even discrepancies in terminology (Scherer SW et al., 2007).  
Nevertheless, emerging technologies are more sensitive for detection of CNVs and provide 
more precise definition of boundaries (Perry et al., 2008). Undoubtedly, as a clearer map of 
human structural genetic variation emerges, we will begin to more comprehensively 
include this type of genetic variation in genome-wide studies that attempt to elucidate the 
role of CNVs in human disease. 
 
 
 
 
1.2.3  Molecular genetics of complex diseases  
 
The plethora of DSVs in the genome and the multilayer regulation of gene expression and 
function are indicative of the intricacy of the determinants of the complex diseases and 
phenotypes. The clinical phenotypes are presumed to result from the additive effects and 
interactions among multiple causative alleles with various genomics and environmental 
factors. In a complex phenotype, the effect sizes of the involved alleles are expected to vary 
and to follow a gradient that ranges from minimal or indiscernible to large and significant 
effect size  (Fig. 4). Only a few alleles are expected to impart large effect sizes and, hence, 
could be detected by the commonly used approaches to genetic studies of complex 
phenotypes. Many are expected to exert modest effects that per se might not be discernible 
based on the usual phenotyping and genetic approaches. A complex trait results from 
confluence of various genetic and non genetic determinants. Genetic factors are major 
determinants of the complex phenotype and this notion is supported by heritability of the 
complex trait (Barabasi et al., 2011). By influencing gene expression, protein structure, and 
function, DSVs could impact various interacting networks that together influence 
susceptibility to a complex phenotype and account for the genetic component of a complex 
trait etiology (Barabasi et al., 2010). 
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Figure 4. Gradients of disease prevalence and the effect sizes of the causative alleles. The prevalence of 
disease, number of determinant DSVs and their effect sizes are shown. Single-gene disorders are caused by 
rare variants with large effect sizes. In addition to the main causal variant, which typically exhibits a 
Mendelian pattern of inheritance, several other non-Mendelian variants contribute to expression of the 
phenotype. On the opposite end of the spectrum are the common complex traits, which are caused, partly, by 
the cumulative effects of a large number of DSVs, each imparting a modest effect size. In oligogenetic 
phenotypes, several alleles with moderate size effects and a large number of alleles with small effect sizes 
contribute to the phenotype (Image by Marian AJ, 2012). 
 
 
The contributing DSVs individually might be neither necessary nor sufficient to alter the 
susceptibility to a complex phenotype. This is in contrast to single-gene disorders, where 
the presence of the mutation typically indicates the expression of disease phenotype,  even 
if with variable penetrance and expressivity. Likewise, the effect size of each contributing 
variant is typically small and often negligible. In general, the effect sizes of DSVs on 
phenotypes are expected to follow a gradient, being the largest for those phenotypes that 
are influenced directly by genes, such as messenger RNAs (mRNAs) and proteins. These 
phenotypes are referred to as proximal phenotypes or endophenotypes. In contrast, the 
effect sizes of DSVs are expected to be smaller for phenotypes that are not influenced 
directly by DSVs, such as clinical outcomes. Such phenotypes are referred to as distant 
phenotypes (Barabasi et al., 2011). The gradient of effect sizes in part relates to the number 
of competing genetic and non genetic factors that contribute to the phenotype. For the 
proximal phenotypes, such as mRNA and protein levels, fewer determining factors are 
expected to contribute to the phenotype, thus each determinant might have a considerable 
effect size. In contrast, for the distant phenotype, such as mortality, many competing 
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genetic and non genetic factors contribute to the phenotype and dilute the effect size of an 
individual DSV (Kathiresan et al., 2008; Debette et al., 2011). 
 
 
 
 
1.2.4 Genetic approaches to complex diseases 
 
The full spectrum of allele frequency in a population is expected to follow a gradient 
ranging from private to extremely common alleles. Conventionally, however, the variants 
are categorized into 3 classes based on their minor allele frequencies (MAFs) in the 
population. Common and rare variants are those that have population MAFs of >5% and 
<1%, respectively. Variants that have population MAFs from 1% to 5% are considered 
uncommon or infrequent (Marian AJ, 2009). As observed for the genetic causes of 
Mendelian diseases, DSVs with large effects are expected to be rare. However, the 
converse is not the rule as most rare variants could have weak or no discernible clinical or 
biologic effects. Likewise, most common variants are expected to exert minimal or 
clinically indiscernible effect sizes. 
Genetic studies of complex diseases might be instigated by a priori knowledge of potential 
involvement of a gene in the pathogenesis of the phenotype, which is referred to as the 
candidate gene approach (Marian AJ et al., 2011).  An alternative is an unbiased 
approach, taking in consideration many genes and variants and typically the entire 
genome, as in GWAS (Genome Wide Association Studies) or NGS (Next Generation 
Sequencing), to identify the associated alleles. Genetic studies of complex phenotypes are 
designed typically on either common disease–common variant (CD-CV) or rare 
variant–common disease (RV-CD) hypotheses (Risch et Merikangas, 1996). 
The former surmises that complex phenotypes results of cumulative effects of a large 
number of common variants, each exerting a modest effect. In contrast, the latter posits that 
multiple rare variants with large effect sizes are the main determinants of heritability of the 
complex phenotypes. Given that the anticipated effect sizes of the alleles in the genome are 
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likely to be a continuum, one might expect a combination of rare, uncommon, and common 
alleles to contribute to heritability of the complex diseases. In a given population, however, 
common alleles, despite having modest effects, might have a greater attributable fraction 
because of their number, even though each rare allele might have a larger effect size 
(Pritchard and Cox, 2002). 
 
 
 
1.3  NEXT-GENERATION SEQUENCING: ORIGIN, RESOURCES AND 
PITFALLS 
 
DNA sequencing techniques have revolutionized our understanding of human biology over 
the last forty years. They originated in the early 70s due to the work of Walter Gilbert and 
Frederick Sanger (Maxam and Gilbert, 1977; Sanger and Coulson, 1975). Continuous 
technological improvements in DNA sequencing instrumentation ever since has created an 
environment in which the Human Genome Project (HGP) (Watson JD, 1990) could be 
finally realized in the year 2001 after a decade of work. The HGP provided the initial draft 
of mankind's DNA sequence by 23 collaborating laboratories using Sanger sequencing of 
mapped regions as well as shotgun sequencing techniques in a process that had a cost ~$3 
billion. The HGP was expected to provide mankind with a dramatic advance in our 
understanding of human health and generate a revolution in personalized healthcare 
approaches. 
Today, Next Generation Sequencing (NGS) techniques represent the next phase in the 
evolution of DNA sequencing technology at dramatically reduced cost and time compared 
to traditional Sanger sequencing (Zhou X et al., 2010).  
Several NGS technologies have been developed using diverse approaches since 2001, each 
with its own distinctive strengths and weaknesses. The major commercial entities which 
came into existence after the success of the HGP include  454 sequencing 
(http://www.my454.com/), Solexa/Illumina (http://www.illumina.com), SOLiD 
(http://www.appliedbiosystems.com), and Polonator (http://www.polonator.org/).  
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The mapping software then attempts to “map” the individual sequence NGS “reads” onto a 
reference genome sequence available from online genome databases. This process is known 
as reference mapping. Alternatively, when the reference genome is unknown apriori, the 
individual “read” fragments are linked to each other by overlapping the common sequences 
at the ends of each read to form a longer, much complete version of the genome under 
study. This is known as denovo mapping of DNA sequence. For the purposes of clinical 
sequencing, reference mapping is performed most of the time due to our pre-existing 
knowledge of the human reference genome sequence (Mardis ER, 2008). 
The first step of NGS data processing is the alignment of reads obtained followed by 
assembly of the genome of the patient sample. Once the alignment process is completed, 
downstream bioinformatics analysis is performed to detect the clinically relevant structural 
genomic alterations. Different software programs are designed to detect different kinds of 
genetic variants: SNPs are the most reliably detected variants in the genome and the most 
abundant; other genomic variants such as indels are equally detected routinely. NGS 
technology also can identify structural variations, like CNVs,  in the genome, although 
routine alignment tools are not suited to perform such analysis since they cannot identify 
more than a few nucleotide mismatches. Thus, specialized software for analyzing indels 
from paired-end reads are being developed which enables identification of structural 
variants by identifying the flanking end regions of the NGS read data (Medved et al., 2010. 
NGS technology supports both whole genome and whole exome sequencing (WGS and 
WES), this last indicating a technique to selectively capture and sequence the coding 
regions of all annotated protein-coding genes. The genome comprises approximately 
180,000 exons that reside in approximately 23,500 genes, therefore, collectively, the coding 
regions encompass about 1% of the genome (Lander et al., 2001). WES requires generating 
a genomic DNA library, capture and enrichment of all exons, and sequencing using a NGS 
platform. 
Despite the high accuracy of base calling by NGS platforms, because of the enormity of the 
data output, the error rate could represent a significant challenge for an accurate 
identification of the variants, particularly for heterozygous alleles or rare variants in a small 
fraction of DNA templates (Ansorge WJ et al.,2009). An important aspect is the coverage 
rate of each allele. 
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In DNA sequencing by the NGS platforms, multiple fragments of DNA are sequenced 
simultaneously, and the outputs are aligned to the reference genome. Thus, it is essential 
that both strands of a diploid genome are represented adequately in the sequence read out. 
In addition, multiple reads of an allele increases the signal to-noise ratio. Therefore, in low-
coverage sequencing, which is more practical because of size of the sequence output, less 
costly, and computationally less laborious, accurate determination of the genotype is less 
certain. In contrast, a higher coverage at each nucleotide increases the confidence in 
accurate allele calling. The coverage rate, however, is often non-homogenous and certain 
genomic regions or exons might not be covered at sufficient depth to provide for accurate 
allele calling (Nielsen et al., 2011). 
Inadequateness of the sequence reads, in part, might reflect inadequate coverage by the 
capture probes. Nevertheless, the gaps could lead to inadequate detection of the variants as 
well as miscalling because of a poor signal-to-noise ratio. Different depth of coverage 
might be necessary according to intended application of the NGS data. 
For instance, in NGS studies in families to detect a causative allele in an autosomal 
dominant Mendelian disorder, a higher depth of coverage might prove essential to detect 
robustly or exclude the presence of a heterozygous mutation. In addition, the relatively 
small number of family members makes high-depth coverage feasible. In contrast, in allelic 
association studies of complex phenotypes, wherein normally sequencing of many cases 
and controls is required, low-coverage is practical and probably a more powerful approach 
than covering a smaller number of individuals at a greater depth. 
 
 
 
1.3.1  Whole Exome  Sequencing: an unbiased approach to study complex 
genetic diseases 
 
Evidently, NGS technology high sequencing accuracy has become of relevant importance 
in the identification of genetic variants that may cause complex inherited diseases. 
The discovery of genetic traits that are at the basis of complex diseases, indeed, has been 
greatly simplified by NGS, apart from the significantly reduced time frame from years to 
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weeks, in the effective identification of rare variants present in the whole genome that 
could exert large effect sizes on the phenotype (RV-CD hypothesis).  
WES it is probably the most commonly used direct DNA sequencing approach today to 
identify the genetic causes of rare Mendelian and common non-Mendelian disorders, 
because of practical reasons including cost, data storage, and bioinformatics analyses. 
The rationale for whole exome sequencing is based on the notion that variants located in 
exons and affect protein sequence are more likely to be pathogenic than those located in 
introns or intergene regions. Thus, the approach posits primarily that infrequent and rare 
nonsense, frame shift, and nonsynonymous DSVs are likely to play major etiologic roles in 
susceptibility to complex phenotypes. 
The whole-exome sequencing approach has been applied successfully to identify of the 
causal mutations for rare Mendelian disorders, such as Freeman-Sheldon syndrome, 
congenital chloride-loosing enteropathy, Kabuki syndromes, systemic hypertension caused 
by hyperaldosteronism, and others (Ng SB et al.,2010; Choi M et al., 2011). 
Exome sequencing, likewise, revealed the complexity of discerning the pathogenic alleles 
based on sequence data alone, as many apparently pathogenic variants might be found in 
clinically unaffected individuals (Klassen T et al.,  2011). 
Efforts are ongoing to apply the whole-exome sequencing approach to delineate the genetic 
causes of common forms of Mendelian diseases, particularly those with an autosomal 
dominant pattern of inheritance, and complex traits. In addition to limitations imposed by 
family size and structure, which could restrict discerning co-segregation of the variants 
with the phenotype, several other limitations render the approach challenging. The 
enormous genetic diversity of the humans and the presence of many variants in each 
genome in conjunction with incomplete penetrance of the causative variants pose 
significant difficulties in establishing a clear genotype-phenotype co-segregation.  
But, if on one side identification of a vast number of rare variants in coding and regulatory 
regions constitutes a successful starting-point to dissect complex diseases, on the other side 
the necessity to effectively analyze the huge amount of WES data and to relate them to 
complex phenotypes is still an open field.  
Interpretation of exome information derived from NGS is still a prickly question. The 
initial approach to establish causality connection is to focus on protein-changing variants, 
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inferring biologic and functional significance by PolyPhen-2 (National Institutes of Health, 
Bethesda, Md) and SIFT (J. Craig Venter Institute, Md) (Adzhubei IA et al., 2010; Kumar 
P et al., 2009) especially those that are rare (low MAF values). Usually 150-1500  private 
variants in the patient are identified as potentially disease causing. Subsequently, there are 
six strategies that could be applied to prioritize these variants (Oetting WS, 2012). The 
choice of the strategy requires  knowledge of the inheritance of the disorder, genetic 
heterogeneity, and availability of family members. The linkage strategy prioritizes variants 
that segregate with the disease or lie within a region that segregate with the disease. 
Whereas, in the homozygosity strategy known consanguinity can help identifying mutations 
associated with a recessive disease. The double-hit strategy  is instead mainly used for 
recessive diseases, by selecting the variants that are homozygous or compound 
heterozygous, and in some cases a single exome can be sufficient to identify the gene 
associated with the disease. In the overlap strategy a well-defined phenotype is the starting 
point and by sequencing multiple unrelated patients with the same phenotype.  The de novo 
strategy, in which  a patient and his parents are sequenced, allows the identification of de 
novo mutations. Finally, the candidate strategy, by using biological information at the 
variant and gene level, can help in finding disease-causing mutations. 
Anyway, there are some potential problems that can limit success: a lack of sequence 
coverage, resulting in the mutation not being targeted; misalignments of reads or miscalling 
of variants; misinterpretation of the variants;  and the over cited clinical and/or genetic 
heterogeneity. 
Notwithstanding these limitations, there is an estimated success rate of 60%  and WES is 
expected to offer and open a full spectrum of genetic determinants of the phenotype in 
Mendelian  and complex diseases (Oetting WS, 2012). 
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2. AIM OF THE STUDY 
 
 
Few monogenic diseases associated with hypercalciuria, renal calcification, and calcium 
nephrolithiasis have been identified so far, and the few genetics investigations by genome 
wide or candidate gene association studies of ICN have produced contradictory results; 
thus, the issue of the genetics of ICN is still awaiting a solution. 
Discovering the genes involved in ICN hopefully will lead to breakthroughs in 
pharmacological targets for treating or preventing these conditions, perhaps to tools for 
diagnosing the risk of developing them, and, finally, but no less importantly, to basic 
science discoveries and a better understanding of renal/intestinal/bone physiology relevant 
to ICN.  
As emerged clearly in the last decade, the approach to molecular genetics has evolved 
considerably, pointing out whole-genome scanning technologies as priority tools to 
investigate genetic basis of complex genetic diseases. 
The choice of the best strategy in a successful genetic analysis requires knowledge of the 
inheritance of the disorder, genetic heterogeneity, and availability of family members. 
Thus, we proposed to study a case-study family in which ICN seems to be mostly an 
hereditary trait and clinical and familiar characteristics are so peculiar to make it a 
candidate ideally suited to be analyzed with this type of approaches. 
The proband, indeed, suffers of a severe form of ICN and, strikingly, he belongs to a family 
with consanguinity in which ICN is present in several members, from both maternal and 
paternal branch (see family tree), and is transmitted in an apparently dominant fashion, with 
males being more severely affected than females. 
MV, 50 years old, since 19 formed calcium oxalate and calcium phosphate renal stones, 
expelling up to date about 300 calculi both spontaneously and by lithotripsy (he underwent 
33 treatments). The metabolic phenotype revealed intermittent hypercalciuria, 
hypocitraturia and phosphaturic tubulopathy.  Pre-calyceal renal cysts were also observed. 
He was resistant to all pharmacological treatments so far adopted.  
MV belongs to a family with consanguinity (his parents are second cousins and both are 
affected by nephrolithiasis). In this family nephrolithiasis is present in several members and 
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is transmitted in an apparently dominant fashion, with males being more severely affected 
than females.  
 
Specific aim of this project was to exploit the potential of CGH array and SOLiD™ 
technology, in combination with new developed bioinformatic tools, in order to identify 
some of the major susceptibility genes involved in ICN. 
Although the ultimate goal of this project was to find answers to medical genetic questions, 
it gave us the fundamental opportunity to elaborate efficient NGS data analysis pipelines. 
NGS technologies, indeed, are still on their infancy as regards appropriate data analysis and 
filtering. Thus, in this context, our role of collaborating unit with specific bioinformatic 
unit (CRIBI, Padova) was critical to evaluate the output of bioinformatic analysis of NGS 
data in order to: identify problems related to the interface bioinformatic tool/ medical-
biological questions; and establish valid criteria of inclusion or exclusion of genetic 
variants for the subsequent biological analyses. This could definitively provide our medical 
and genetic expertise to help in the development of a more user-friendly bioinformatic tool 
(QueryOR) and NGS data analysis guidelines. 
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3. MATERIALS AND METHODS 
 
 
3.1 CASE-STUDY  
 
MV, 50 years old, since 19 formed calcium oxalate and calcium phosphate renal stones, 
expelling up to date about 300 calculi both spontaneously and by lithotripsy (he underwent 
34 treatments). He has been followed for thirty years by prof. D’Angelo (Nephrology 
Division, University of Padova). 
The metabolic phenotype revealed: 
 alternatively absolute (>300 mg/die) or marginal (UCa/Cr >0,14) idiopathic 
hypercalciuria; 
 persistent hypocitraturia (≤0,95 mmol/die); 
  phosphaturic tubulopathy: TRP<80% and  TmPO4/GFR < 2.2 mg/dl, with salt 
depletion; 
 absence of thyroid and parathyroid metabolism alterations; 
 very recently, bilateral pre-calyceal renal calcifications were also observed; 
 resistance to all pharmacological treatments so far adopted (thiazide diuretics, 
assumption of crystallization inhibitors as citrate and magnesium,  abundant 
hydrotherapy). 
Interestingly, MV belongs to a family with consanguinity (his parents are second cousins, 
both affected by nephrolithiasis). In this family ICN is present in several members (Fig. 5) 
and is transmitted in an apparently dominant fashion, with males being more severely 
affected than females.  
The most striking clinical characteristics of family members are reported below. 
 Father: bilateral symptomatic recurrent nephrolithiasis that led to monolateral 
nephrectomy.  
 Paternal grand-father: recurrent nephrolithiasis, similarly to the father. 
 Mother: nephrolithiasis diagnosis with constant “renella” emission, hypocitraturia 
and hypomagnesuria; 
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 Maternal (2/2) and paternal (3/3)  aunts affected by recurrent nephrolithiasis, with 
one of the maternal branch certainly presenting hypocitraturia.  
 Nephew (maternal branch): presenting a diagnosis of bilateral microlithiasis, 
constant “ renella” emission, hypophosphoremia and sporadic hypocitraturia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Genealogical tree of the case-study family. 
 
 
From both clinical and metabolic points of view, the ICN encountered in this family does 
not present any of the characteristics of the monogenic forms. Nevertheless, the proband 
and affected and not affected family members have been analyzed for the presence of 
mutations /variations in candidate genes known to have a role in nephrolithiasis such as 
CLCN5 (in the suspicion of Dent’s disease) and CaSR genes, but any relevant findings 
have been found. 
 
 
? 
(mild phenotype) 
?   Unknown phenotype   
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3.2 GENOMIC STUDIES 
 
3.2.1  DNA extraction and purification, PCR amplification  
 
Peripheral blood leucocytes DNA was extracted by using  QIAamp® DNA Blood Mini Kit 
(QIAGEN, CA, USA), following the indicated protocol. 
DNA was lately quantified with NanoDrop ND-1000 (Celbio, Italy) and its purity was 
checked basing on A260/A280 ratio (between 1,8 and 2).  It was subsequently used for 
needed applications or stored at -20°C. 
PCR amplification was performed on myCycler thermal cycler (Bio-Rad, Italy) using a 
DNA working concentration of 25 ng in a reaction volume of 25 µl.  Reaction mix 
constituents were:  1mM or 1.5 mM MgCl2 (Sigma, MO, USA), 0.4 mM forward and 
reverse primers (Eurofins MWG Operon, Germany), 0.2 mM dNTPs (Boehringer, 
Germany), 0.04 U/ml JumpStart Taq DNA Polimerase (Sigma, MO, USA), 50mM KCl 1X 
buffer  (Sigma, MO, USA), and 10 mM Tris-HCl (pH 8.3). 
 
PCR program used is detailed below: 
   Step 1. 95 °C, 5 min (Denaturation) 
   Step 2. repeated per 40 cycles (Amplification) 
               94 °C, 45 sec  
               T °C, 45sec (annealing T variable basing on primer sets)   
               72 °C, 1 min 
   Step 3. 72 °C, 7 min (Final extension) 
 
If following sequencing applications were needed amplified DNA was further purified to 
remove residuals of all PCR reaction components (nucleotides, salts, polymerase,etc.) with 
MinElute® PCR Purification Kit (QIAGEN, CA, USA). 
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3.2.2 Primer design and optimization 
The DNA sequence for a gene or for a genomic region was retrieved from the UCSC 
genome browser (http://genome.ucsc.edu).  
Primer pairs for the region of interest were designed according to stringent parameters to 
ensure successful assays and convenient experiment design, by using Primer3Plus software 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi). Subsequently, the 
generated primers were  subjected to in silico validation to avoid single nucleotide 
polymorphisms (SNPs) and copy number polymorphisms at the annealing sites.  These 
were excluded at the annealing sites using the corresponding tracks from the UCSC 
browser (in silico PCR tool) to open the Genome Browser at the position of the amplicon. 
The BLAST program from the NCBI browser (http://www.ncbi.nlm.nih.gov/BLAST/) was 
used for in silico specificity analysis.  
Anyway, after thorough in silico quality control, an extensive empirical validation of the 
primer pairs was performed. First, amplification efficiencies are calculated based upon the 
generation of standard curves using genomic DNA (gDNA) dilution series. Subsequently, 
melting curve analysis, acrilamide gel electrophoresis or microchip electrophoresis (2100 
BioAnalyzer, Agilent) were used to check the specificity of the PCR reactions. 
 
 
3.2.3 CGH array analysis, CNVs detection and characterization 
 
CGH arrays has been performed in the proband and in eight members of the family in order 
to detect the presence of Copy Number Variants (CNVs) in the genome, in collaboration 
with Dott. Zavan (Laboratory of Tissue Engineering, University of Padova). 
Slide array 4x44K and 4x180K Agilent (Agilent Technologies) were used, ensuring a 
resolution of about 80-100 Kb and 13 kb, respectively. Map position was in accord to 
genomic assembly of March 2006. Analysis was carried out with Feature Extraction and 
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CGH-Analytics software. Evaluation of results based on Genome Assembly 2006 (hg18), 
UCSC Genome Browser and DGV (Database of Genomic Variants).  
DGV (https://decipher.sanger.ac.uk/)  is a database that provides a comprehensive summary 
of structural variations (larger than 50bp) in the human genome of healthy control samples.  
Gene database at NCBI (http://www.ncbi.nlm.nih.gov/gene) was lately used to clarify CNV 
genetic content. 
 
 
 
3.2.3.1 Real time CNV-profiling 
For copy-number determination, a qPCR assay was developed. In particular it has been 
used to dose particular genomic fragments of Xq22.2 region, allowing a correct 
quantification of the presence of one, two or more copies. This assay was set up on 
available members of the case study family and lately  
Dedicated design of the qPCR primers and extensive in silico validation were the starting 
points, as detailed above.  
Experiment design was the subsequent but indispensible (but often overlooked) step in the 
workflow of accurate real-time PCR based genomic quantification. Reference assays were 
included in the screening to accurately measure and correct for variations in the total 
amount of input DNA. These assays amplified a piece of genomic DNA that is known not 
to be affected (i.e. not registered as a known copy number polymorphism). Most autosomal 
inherited genes with an essential function, not related to the studied phenotype, can be used 
as a reference sequence. We have used an assay amplifying GPR15 genomic DNA as 
references for normalization of the qPCR data since 2005 (RTprimerDB #1022, 
http://www.rtprimerdb.org) (Lefever et al., 2009) At least two types of control samples 
should be included in every qPCR-based copy number analysis. “No template controls” 
were included to detect the presence of contaminating DNA. Specific for qPCR-based copy 
number analysis, was the inclusion of reference samples with a known copy number. 
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During calculations and result interpretation, these control samples were used as a reference 
point (or calibrator) for the determination of the copy numbers. The inclusion of multiple 
reference samples result in more accurate results. We used two samples, one with a normal 
and the other with a known CNV. The latter CNV sample with known Xq22.2 duplication 
served as reference point and as positive control for the detection of CNVs.  
A list of primers sequences used in this study is showed below in Table 2. 
 
Table 2. Primer sequences used in CNV-profiling assays. 
Primer name Forward sequence Reverse sequence 
gGPR15 GGTCCCTGGTGGCCTTAATT TTGCTGGTAATGGGCACACA 
gNUP62CL TTAGTGTAGTAGCAACTCCTG   CTCAATCAATGTATGGTCCC 
gRBM41/I TCCTCAATTGCAGTGGTCTG TGATACATGTTACCAGGGGCA 
gRBM41/II GAAGAGTGATGAGCATGTCCT   CATACATTCCTCAATGGAGACAG 
gCXorf41 TGGAATGTACCAGTGCCAAA TCTTTTTCATGCAGTTTCAGAAG 
 
Real-time quantitative polymerase chain reaction (qRT-PCR) was performed to quantify 
genomic DNA levels, using SYBR Green technology. The principle consists in the 
quantitative relationship that exists between the amount of starting material (target 
sequence) and the amount of PCR product at any given cycle. When amplifying the DNA, 
an increasing amount of double-stranded DNA is created, which binds the Sybr® Green 
(fluorescent) probe resulting in an increase of fluorescence. By plotting the increase in 
fluorescence versus cycle number it is possible to analyze the PCR kinetics in real-time 
(Pfaffl, 2001). For each fragment to analyze, a reaction mix was made (15 µl final volume), 
prepared as follows: 7,5 µl of iQ SYBR Green Mastermix (BioRad, Italy); 4,55 µl of milliQ 
water; 0,225 µl of 20 µM Forward Primer (300 nM);  0,225 µl of 20 µM Forward Primer 
(100 nM); 0,5 µl of 5 µM Reverse Primer (300 nM). An overview of the primers used is 
given below in Table 2. The reaction mix was loaded, 12,5 µl/well, in 96-well plates 
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(BioRad, Italy) and 2,5 µl of the DNA of interest was added to each well. The plate was 
subsequently loaded on iCycler thermal cycler (BioRad, Italy). 
To ensure quality control on the precision and accuracy of the obtained qPCR data, provide 
better accuracy, we used 3 technical PCR replicates and a 3-points standard curve) with a 
dilution factor of 10 (starting from 10 ng/µl concentration). 
PCR reactions were performed on the iCycler  (BioRad, Italy). 
The PCR  program used is detailed below: 
Step 1: 50°C, 2 min (Incubation) 
Step 2: 95°C, 2 min 
Step 3: 95°C, 15 sec (Denaturation) (Step 3, repeated per 40 cycles) 
             60°C, 45 sec (Extension) 
Step 4: 95°C, 15 sec (Dissociation) 
Step 5: 60°C, 20 sec (Melting curve) 
Step 6: 95°C, 15 sec 
The level of each genomic fragment was always compared to GPR15(G protein-coupled 
receptor 15), the housekeeping gene used as reference assay, level calculating the ∆Ct 
sample value as follows: Ct genomic fragment – Ct GPR15. The ∆∆Ct was calculated subtracting 
∆Ct calculated for the calibrator (∆Ct sample – ∆Ct calibrator). Finally, the ultimate calculation 
to obtain genomic DNA level of each fragment was 2^(-∆∆Ct). 
 
 
 
 3.2.3.2 CNVs  burden in case and “control” cohorts 
 
In collaboration with Dott. Sanna Cherchi (Division of Nephrology, Columbia University, 
New York), CNVs burden in control cohorts was examined. 
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The “control” group consisted of 14,375 anonymized adults and children: these are not to 
be considered as properly defined control in our ICN study because they were collected for 
allowing another kind of genetic studies, on renal developmental abnormalities, and 
therefore we cannot exclude that they were eventually affected by ICN. 
Two cohorts consisted of white European affected individuals recruited from pediatric 
centers in Italy, Poland, Macedonia, Croatia, and the Czech Republic. All cases were 
unrelated. Inclusion criteria included the presence of a primary renal-parenchyma defect—
such as renal agenesis, a congenital solitary kidney or renal hypodysplasia (finding of a 
small or cystic kidney for age). Another cohort consisted of 134 multiethnic North 
American individuals (63% white, 23% African American, and 10% admixed) diagnosed 
with renal hypodysplasia. Additionally,  six cohorts of European (80,4%), Asian (13,4%), 
and African American ancestry (6,1%), were examined: they were genotyped on high-
density Illumina platforms as cases or controls for genetic studies of complex traits not 
related to any developmental phenotypes. 
The CNV-profiling assay was applied to screen a case cohort of 85 ICN patients (collected 
by prof. Gambaro G., Catholic University of Rome; and Dott. Fabris A., University of 
Verona). 
 
 
 
3.2.4 Whole Exome Sequencing analysis, data filtering and validation 
 
Whole Exome Sequencing of the proband was performed (in collaboration with prof. Valle 
G., CRIBI, Padova) with SOLiD 5500xl sequencer, at an average 15X coverage. 
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3.2.4.1  Exome sequencing data analysis: criteria for identifying single-
nucleotide and copy-number variants 
 
 To analyze and filter single-nucleotide variant findings, we used QueryOR platform, a 
web-based query platform that aggregates several functional annotation of variants and 
genes (developed by Bioinformatic group, CRIBI, prof. Valle G., Padova), for giving 
valuable prioritization criteria and reduce the search space of analysis of exome sequencing 
data. The prioritization strategy consist in a ranking system that sorts results based on the 
satisfied criteria, in contrast with other developed tools that applies filters to reduce the 
results.  
We generally applied two criteria of search to identify the most promising variant call set: a 
gene-centered search, starting from known notions about genes and focusing attention on 
those that harbored promising variants; a variant-centered search, starting from characteristic 
intrinsic to the variants per se like type (sense, missense, nonsense), homozygosis and 
genomic position. 
For missense variants, we generally applied a subsequent prioritization strategy by ranking 
variants on the basis of query coverage, low MAF (Minor Allele Frequency) values (< 0,001) 
and a possibly-probably damaging/deleterious prediction (PolyPhen/SIFT prediction tools), as 
could be inferred from QueryOR reports. 
To investigate the possible pathogenic significance of sense variants, we used ASSEDA 
software (Automated Splice Site and Exon Definition Analysis, http://splice.uwo.ca/) that 
allowed to study the effect of a single nucleotide variant in modificating canonical splicing, 
with the prediction of activation an strenght of criptic sites of splicing. 
 
To investigate the presence of CNVs we filtered exome sequencing data with bioinformatic 
software developed by CRIBI Genomics that allow the detection of small structural 
variations. 
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3.2.4.2 Molecular validation and segregation study 
 
Because  NGS technique is not exempt from errors and a low percentage of false positive 
calls always exist, variants that passed the in silico  prioritization strategy were submitted to 
molecular validation by Sanger sequencing. This validation step was performed on proband’s 
DNA. Furthermore, once the variant was confirmed, we extended the validation procedure to 
the other members of the family to perform a segregation analysis. 
Primer were designed, as detailed above, to sequence a genomic fragment that contained the 
single-nucleotide variant to be confirmed; primer sequences are listed below (Table 3). PCR 
reaction and purification were performed as previously described. 
 
Table 3. Primer sequences used for single-nucleotide variant validation  
Primer name Forward sequence Reverse sequence 
gNCX1/rs148215685 AGCACAAAGAGGCAGGATGT CATCGCTGCCATCTACCAC 
gNUP62CL/rs1285590 CTGTCACAGCAGCAGGAACT ACATCTCCACATGCTCCTCA 
gNUP62CL/rs1298577 CTGTCACAGCAGCAGGAACT ACATCTCCACATGCTCCTCA 
gATP6V1B1/rs11681642 CCAGCTGGACCTGAAGTCTC GGCCTGCTGTCTATCTCCAT 
gATP6V1B1/not known  CTAACACTCCCTCCCGCTCT CGGGAATAGAACTCGTCGAT 
gFGF23/not known TAATTCACTTCAACACCCCCA TCGGGAGCTCCTGTGAACAG   
gHNF1B/not known GCAATTACTCCATGATTATGCTACTT ATGTGAATTATTTGATTAAAATCTGA 
gXDH/ rs45624433 CTGAGCCTCACCTGTCCAAT TCTGCTTGGGAACGTACTCT 
gXDH/ rs17011368 CTGCTTCGGAAAACCCCTTC CAGCTGAGGAAATGGAGGAA 
gUSP29/ rs9973206 AGAACTTTTTCCCGAAATGGA CCGGGAATTTCTCTCTTGAA 
gKCNS1/not known AAAGGCGAAGACGCACAGCTCGT AGGGAGGAGCACTGAAACCT 
 
 
Sequencing reaction of PCR products was set up by using BigDye® Terminator v1.1 Cycle 
Sequencing Kit (Applied Biosystems, CA-USA), with a purified amplified DNA concentration 
of 2 ng/ µl. For each PCR product to be sequence, a reaction mix was made (10 µl final 
volume), prepared as follows: 2 µl Terminator Ready Reaction Mix; 0,5 µl Forward or 
Reverse primer 3.2 µM; 5,5 µl milliQ water. 
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Sequencing program is detailed below: 
   Step 1. 96 °C, 1 min  
   Step 2. repeated per 25 cycles  
               94 °C, 10 sec  
               50 °C, 5 sec  
               60 °C, 4 min 
 
Sequence products were lately stored at -20°C or immediately processed to purification. 
Tagged terminators not incorporated in the reaction were subsequently removed through 
CENTRISEPT Spin Columns (Princeton Separations, Applied Biosystems, USA). 
Elution product was later loaded on sequencing plate and read on 3130 Genetic Analyzer 
(Applied Biosystems). 
Sequences were displayed with Chromas 1.45 tool and compared to genomic sequence by 
performing BLAST (bl2seq) (http://www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi), or using 
UCSC Genome Browser to investigate the presence/absence of the detected variant. 
 
 
 
3.3 TRANSCRIPTIONAL STUDIES 
 
3.3.1 RNA exctraction, quantification and cDNA synthesis  
 
RNeasy Micro Kit (Qiagen, cat no. 74004) was used to isolate total RNA from leucocyte 
cells, following the spin column protocol. RNA was finally eluted in RNAse free water and 
stored at –80°C. 
RNA concentration was measured with  Nanodrop  ND-100 spectrophotometer (Celbio, Italy) 
and purity was checked by the A260/A280 ratio (between 1,8 and 2). 
RNA integrity was valued by capillary electrophoresis on chip with Agilent 2100 Bioanalyzer 
(Agilent Technology), by observing and quantifying integrity of 28S and 18S rRNAs. 
We routinely performed two-step RT-PCR reactions, in which the first step is cDNA 
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synthesis. This protocol allowed us to make cDNA by using MuLV DNA polymerase starting 
from a single-strand RNA template.  
RNA was retro-transcribed from a starting quantity of 100 ng in a  reaction volume of 20  µl. 
Reaction mix was prepared as follows: 4 µl MgCl2 25 mM (Sigma); 2µl dNTPs 10 µM 
(Roche); 1µl random examers 50 µM (Applied Biosystem); 1µl RNAse inhibitor 20 U/ µl 
(Applied Biosystem); 1µl MuLV inverse transcriptase 50 U/ µl (Applied Biosystem), 2µl 
Buffer 10X (Sigma) constituted by KCl 50 mM e Tris-HCl 10 mM (pH8.3) and milliQ water 
to reach the final volume.  
Reaction was performed on iCycler thermal cycler by applying the following protocol: 
      Step 1. T amb, 10 min  (Primer annealing) 
      Step 2. 42 °C, 30 min (Primer extension) 
      Step 3.  65 °C, 5 min  (Denaturation) 
      Step 4.  4°C, 5 min (Cooling) 
 
 
3.3.2  Quantification of gene expression:  Real Time PCR 
 
Real-time quantitative polymerase chain reaction (qRT-PCR) was performed to analyze gene 
expression levels, using iQ SYBR Green SuperMix (BioRad, Italy) as detailed above. 
For each fragment to analyze, a reaction mix was made (15 µl final volume), prepared as 
follows: 12,5 µl of  iQ SYBR Green Mastermix; 4,55 µl of milliQ water; 0,225 µl of 20 µM 
Forward Primer (300 nM) and  0,225 µl of 20 µM Reverse Primer (300 nM) (MWG Operon, 
Germany). An overview of the primers is given below in Table 4.  
 
Table 4. Primer sequences used for expression study. 
Primer name Forward sequence Reverse sequence 
NCX1 TGAATTCAAGAGTACTGTGGAC TGCATCACGTAATCGAAACAG 
MORC4 ACCTACCTTCACAAATAAGCAG ATTACTCCTACACCTTCTCCA 
NUP62CL ACTGTTAGTGTAGTAGCAACTCC CATTCTCAATCAATGTATGGTCCC 
CLDN2 TGTCTTCTAGATGCCTTCTTGAG CAGACCTCTCAGTAGAAGCG 
PRPS1 TAAGAAAGATAAGAGCCGGGC CTCTGCATACAAATTGTCTACTGG 
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The reaction mix was loaded, 14 µl/well, in 96-well plates (Bior) and 1 µl of the DNA of 
interest was added to each well. 
PCR reactions were performed on the iCycler  (BioRad, Italy). The PCR  program used is 
detailed below: 
Step 1: 50°C, 2 min (Incubation) 
Step 2: 95°C, 2 min 
Step 3: 95°C, 15 sec (Denaturation) (Step 3, repeated per 40 cycles) 
             60°C, 45 sec (Extension) 
Step 4: 95°C, 15 sec (Dissociation) 
Step 5: 60°C, 20 sec (Melting curve) 
Step 6: 95°C, 15 sec 
 
The expression level of each gene was  always compared to GAPDH (Glyceraldehyde 3-
phosphate dehydrogenase) (forward: GAAGGTGAAGGTCGGAG; reverse:  
TGGCAACAATATCCACTTTACCA)  housekeeping gene calculating the ∆Ct sample 
value as follows: Ct gene – Ct GPR15. The ∆∆Ct was calculated subtracting ∆Ct calculated for 
the calibrator (∆Ct sample – ∆Ct calibrator). Finally, the ultimate calculation to obtain the 
relative gene expression was 2^(-∆∆Ct). 
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4. RESULTS AND DISCUSSION 
 
4.1   CGH ARRAY ANALYSIS:  DISCOVERY OF A NOVEL CNV 
 
To investigate the presence of CNVs  in the case study family, we performed CGH array 
analysis on all available family members. 
We found the presence of a duplication of 308,398 Kb of chromosome X q22.2 region in 
the proband and in other three family member (Fig. 6). This duplication having START at 
106,126,808 and STOP at 106,435,205 chrX positions (basing on hg18 Assembly), 
respectively. 
 
 
 
Figure 6.  Feature extraction software visualization of CGH results: the Xq22.2 duplication of 308,397 Kb is 
evidenced by the probes (circled red dots) that overlie in the +1 axis; results are shown for three over four 
family members that harboured the Xq22.2 duplication. 
 
 
As can be inferred by the genealogic tree in Fig. 7, three over four family members that 
present Xq22.2 duplication are certainly affected. Thus, this seemed a first hint indicating 
the striking importance of this finding. Furthermore, by consulting the available public 
database we found that this was a novel CNV, because it resulted absent in the DGV 
(Database of Genomic Variants).  
47 
 
Strikingly, this last finding seemed to indicate that we encountered certainly a very rare 
copy-number variant.  
The CNV has been inherited from the affected mother and was also present in the maternal 
affected aunt. However this variant cannot be shared by the paternal branch since the 
progenitors of maternal and paternal branch are two brothers (see family tree, Fig. 7). Thus, 
we hypothesized that additional genetic determinants have been inherited from the paternal 
branch. Alternatively, the Xq22.2 duplication might be the result of an X/autosome 
balanced translocation occurred in one of the common progenitors and segregating 
differently in the descendents of maternal and paternal branches. 
 
 
 
 
Figure 7. CGH array analysis pin the case-study family. It was performed in nine family members (as 
indicated by the asterisk) and the Xq22.2 duplication was detected in the four members tagged with the red 
bar.  
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Considering the intriguing finding, we started to deeply investigate the duplicated Xq22.2 
region by analyzing its genetic content. By extracting information from the Feature 
Extraction Software,  we could infer which genes were identified by the probes that 
resulted with a double signal (Fig. 8) and by comparing it with Gene database we could 
clarify that three genes were included in the duplicated region: RBM41, NUP62CL and 
CXorf41. This was subsequently confirmed by UCSC Genome browser analysis (Fig. 9). 
RBM41 gene encodes for the RNA binding  motif protein 41; NUP62CL (nucleoporin 62 
C-terminal like) is an homolog gene of nucleoporin 62, NUP62; CXorf41 or PIHD3 (PIH1 
domain containing 3) is a gene  implicated in a positive regulation of human rRNAs. 
 
 
Figure 8.  Feature extraction software frame showing in columns the probes used to perform the CGH 
analysis in the Xq22.2 region, indicating for each one its name, start and stop positions. The name of the 
corresponding gene is also shown. Data shown are relative to  Human Mar. 2006 (NCBI36/hg18) Assembly. 
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Figure 9.  UCSC GENOME Browser frame illustrating the Xq22.2 duplication of 308,398 Kb, with the new 
genomic coordinates  (chrX: 106,240,152-106,548,549) updated to  Human Feb. 2009(GRCh37/hg19) 
Assembly. 
 
 
 
 
 
4.2  Xq22.2 CNV IN-DEPTH ANALYSIS: TRANSCRIPTIONAL STUDY 
 
Most copy number variants exist in healthy individuals; however, these variants are 
hypothesized to cause diseases through several mechanisms. First, copy number variants 
can directly influence gene dosage through insertions or deletions, which can result in 
altered gene expression and potentially cause genetic diseases.  
Gene dosage describes the number of copies of a gene in a cell, and gene expression can be 
influenced by higher and lower gene dosages (Feuk et al., 2006). For example, deletions 
can result in a lower gene dosage or copy number than what is normally expressed by 
removing a gene entirely (Fig. 10a). Deletions can also result in the unmasking of a 
recessive allele that would normally not be expressed (Fig. 10b). Structural variants that 
overlap a gene can reduce or prevent the expression of the gene through inversions, 
deletions, or translocations (Fig. 10b). Variants can also affect a gene's expression 
indirectly by interacting with regulatory elements. For instance, if a regulatory element is 
deleted, a dosage-sensitive gene might have lower or higher expression than normal 
(Fig.10c). Sometimes, the combination of two or more copy number variants can produce a 
complex disease, whereas individually the changes produce no effect (Fig. 10d).  
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Figure 10.  Influence of structural variants on phenotype ( Image by Feuk et al., 2006). 
 
 
Some variants are flanked by homologous repeats, which can make genes within the copy 
number variant susceptible to nonallelic homologous recombination and can predispose 
individuals or their descendants to a disease (Freeman et al., 2006). Additionally, complex 
diseases might occur when copy number variants are combined with other genetic and 
environmental factors (Feuk et al., 2006). 
We firstly decided to examine Xq22.2 duplication effect at gene expression level and, by 
taking all the over cited basics in considerations, we planned a well comprehensive 
expression study.  
In brief, we  considered both genes strictly included in the duplicated region, both genes 
situated slightly upstream or downstream, and genes that could be influenced by a long-
range position effect (Kleinjan and van Heyningen, 2005). 
Thus, we set up our expression study taking in consideration five candidate genes. The 
nucleoporin NUP62CL, that is the only gene strictly included in the Xq22.2 duplication 
region. MORC4, that encodes for a protein containing an ATPase domain and a Zinc-finger 
domain crucial for protein-.protein and protein-DNA interactions. CLDN2, that encodes for 
a claudin of epithelial and endothelial tight junctions  responsible of small ions and solutes 
transport. PRPS1 (phosphoribosylpyrophosphate synthetase 1), whose overexpression has 
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been found linked to a genetic disorder characterized by hyperuricemia and hyperuricosuria 
(De Brouwer et al., 2008).  Finally, we also considered a gene not contained in the X 
chromosome, NCX1 (sodium/calcium exchanger member 1), because it could be 
influenced by a long-range positional effect. Upstream the duplicated region, indeed, it is 
located FXYD6P3 gene, belonging to a family of ion transport regulators that in some 
tissues regulate the NCX1 exchanger (Cheung et al., 2013). This gene, in the kidney, is 
responsible of calcium extrusion from the basolateral membrane, and for this reason it 
represents a good candidate for ICN, even if it has never been analyzed in human 
nephrolithiasis.  
Examining gene expression in leucocytes of control and mutated members (harboring 
Xq22.2 duplication), we found a significant increase in the expression of NCX1 in the 
mutated family members (Fig. 11). Thus, considering its role in the kidney, our results 
point it out as possible susceptibility gene for ICN.  
We either detected a decrease in expression of CLDN2 and NUP62CL, even though it 
could not be assumed as significant (Fig. 11). 
 
 
 
 
Figure 11. Expression levels of the five candidate genes are shown in the graph. Results are referred to 
leucocytes samples. 
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Subsequently, we could analyze expression levels of the candidate genes on fibroblast 
samples taken from a bladder biopsy of our proband  and we compared them to control 
fibroblasts. 
Interestingly, NUP62CL gene showed a significant and huge decrease in the expression in 
the proband sample, compared to controls (Fig.12). 
 
 
Figure 12. Expression level of NUP62CL gene in fibroblast samples. 
 
 
This last finding appeared  particularly appealing in our ICN susceptibility genes search, 
NUP62CL being the homolog of NUP62, also known as nuclear pore complex oxalate 
binding protein 62. This protein, indeed, mediates oxalate transport from the cytoplasm into 
the nucleus and its expression has been found increased in experimental hyperoxaluria 
(Sivakamasundari et al., 2004), a common metabolic condition in ICN patients (Asplin et 
al., 2002). In recent years, our proband did not show the intermediate phenotype 
hyperoxaluria but, at his nephropathy exordium, he formed calcium oxalate stones. 
Furthermore, the over cited studies, dealing with an in vitro mimicked hyperoxaluria, prove 
a clear modulation of NUP62 by oxalate. Therefore, the down-regulation that we observed 
well fits in this scenario. 
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4.3  GENOMIC  STUDIES 
 
4.3.1 Characterization of Xq22.2  duplication and “case-control” study 
 
Real-time PCR represents, indeed, the golden standard for a quick and reliable 
confirmation of CGH findings (D'haene et al., 2011).  
Thus, we firstly served of our case study family to set up a CNV-profiling assay, to detect 
and confirm the presence of one, two or three copies of the Xq22.2 region in object (see 
materials and methods). We initially chose a genomic fragment encompassing a region 
contained in NUP62CL gene (chrX: 106,397,338-106,397,480, hg19), that was the gene 
lying in the center of the duplicated region.  
The chosen genomic fragment resulted effectively capable to discriminate the different 
genomic profiles in the case-study family: dealing with a chrX region, indeed,  we detected 
a single dose for normal males, a double dose for mutated males and normal females and a 
triple dose for mutated females (Fig. 13). 
 
 
 
Figure 13. CNV-profiling assay set up. The NUP62CL genomic fragment resulted quantitatively reliable in 
the discrimination of the different genomic profiles. Samples 1 and 2 stand for two family members each one 
for each category (normal males, Xq22.2 CNV males, normal females and Xq22.2 CNV females). 
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Lately, we tested three more genomic fragments to confirm and better characterize the 
Xq22.2 duplication. We chose two fragments in the proximity of START and STOP 
regions, RBM41/I (chrX:106,312,496-106,312,608) and CXorf41 (chrX:486,428-
106,486,544), respectively; and another fragment lying more centrally in the duplicated 
region, but upstream the first one tested (NUP62CL), RBM41/II (chrX:106,359,873-
106,359,981). By observing the underlying graph (Fig. 14a), it appears clear that the 
fragment proximal to START region, RBM41/I, actually did not seem internal to the 
duplication because both normal and mutated (Xq22.2 CNV) males presented a single dose 
(near to 100%).  
 
 
   
 
Figure 14. CNV-profiling for 
breakpoint characterization. a) 
RBM41/I (chrX:106,312,496-
106,312,608) fragment is present in 
single dose in both normal and Xq22.2 
CNV males. b) RBM41/II 
(chrX:106,359,873-106,359,981) is 
present in single dose in normal males, 
but in double dose in Xq22.2 CNV  
males. c) CXorf41 (chrX:486,428-
106,486,544) fragment is duplicated in 
Xq22.2 CNV males, as well. 
 
a) b) 
c) 
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Whereas, both the more internal fragment RBM41/II and the fragment proximal to the 
END region, CXorf41, resulted effectively duplicated in mutated males, presenting a 
double dose compared to the single one of normal males (Fig. 14b and c). 
These results confirmed that the males of the case-study family in which CGH array 
analysis detected the Xq22.2 duplication effectively presented a double dose of genomic 
fragments lying in the central and END regions, contrarily to the normal condition of 
hemizigosis. However, they even indicated that the START breakpoint of the duplication, 
as detected by CGH array analysis, needed to be refined more precisely because in this case 
the presence of the duplication was not confirmed. Furthermore, taken all in consideration, 
these results proved once more the reliability and necessity of a quantitative assay to 
validate CGH findings. 
 
To deeply investigate the frequency and pathogenic significance of the novel Xq22.2 
duplication we performed a collaboration study, with Dott. Sanna Cherchi (Columbia 
University), in which we screened a cohort of 14375 individuals (more than 10000 
caucasians), previously characterized  for the presence of any CNVs.  
Eminently, we found 16 individuals harboring CNVs overlapping our Xq22.2 CNV region, 
of which only 5 were duplications (Fig. 15).  
Notably, the genetic content common to all the five duplication overlapping our Xq22.2 
duplication is represented by NUP62CL gene. 
This result, due to the size of the control cohort considered, confirmed the extreme rarity of 
Xq22.2 duplication that we found in the case-study family and highlighted a possible 
significance of NUP62CL gene.  
Nonetheless, dealing with a cohort of individuals coming from a different pursued study, 
these individuals were not selected for having no nephrolithiasis condition, thereby could 
not be considered as pure controls. We cannot exclude, indeed, that, ICN being a common 
disease, some of those 16 individuals were eventually affected by ICN. This would have, in 
case, strengthened more and more the hypothesis of Xq22.2 duplication association to ICN. 
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Figure 15. List of the 16 CNVs overlapping Xq22.2 CNV detected region. CN_State describes the type of 
CNV: 0= homozygous deletion, 1= heterozygous deletion, and 3= heterozygous duplication (highlighted in 
gray). 
 
 
To better clarify the possible association of the detected duplication with the pathogenesis 
of ICN, we applied the CNV-profiling assay to screen easily a case cohort of 85 ICN 
patients for the presence of  Xq22.2 duplication. In this case, CNV profiling did not 
evidenced any duplication in sample individuals. 
Thus, this result did not actually prove the effective association of the Xq22.2 duplication, 
per se, with ICN. Even though, it is still possible that the case cohort screened was too 
small to be realistically representative of an ICN population, also considering that we deal 
with a very heterogeneous disease both for cause and manifestations (Taylor et al., 2005; 
Worchester and Coe, 2008). 
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4.3.2 Whole exome sequencing: chrX CNV detection and validation 
 
As mentioned before, although the primary necessity and achieved goal of WES is to obtain 
the sequence of an entire exome, subsequently it emerged clearly as it can serve as  
valuable instrument to afford CNV detection, as well as its breakpoints characterization 
(Kidd et al., 2008). 
In collaboration with prof. Valle (CRIBI, Padova), we performed WES of the proband and 
subsequently we applied some public and home-made bioinformatic tools to detect the 
presence of CNVs in the chrX of the proband. 
Normally, analyzing WES data, we consider a duplication that unique region in the exome 
that shows a coverage unusually over the mean coverage, whereas for putative deletions we 
should observe a signal depletion, that stands for no coverage at all. 
In this chrX circle map (Fig. 16) four different traces are plotted to indentify CNVs and 
discriminate them from false positives. All these traces were obtained measuring the mean 
coverage signal of a 100,000 base pairs window, with progressive steps of 10,000 bases 
(overlap region of 90,000 and resolution of 10 Kb). 
Considering the CNV trace (Fig. 16), we could observe 4 blue-colored regions from 
positions 105 to 120 (corresponding to chrX coordinates) that seem to be duplications. 
Nonetheless, only the duplications lying nearby positions 106 and 110 are to be considered 
realistic (Fig. 16). This is true because those are the only two that present a significant 
signal in both BEST-HIT and UNIQ traces, representing multiple and unique alignments in 
the exome respectively. 
Taken all these results in consideration, we could firstly confirm the Xq22.2 duplication, 
beforehand identified by CGH array, and gain the previously unknown information about 
its occurrence in tandem on chrX. This first result identified this duplication with START 
and STOP at chrX:106,305,001-106,625,001, with 10 Kb resolution (Fig. 17), therefore it 
seemed shifted of 55,849 base pairs in respect to the precedent identification.  
 
Unexpectedly, we discovered another duplication lying 70 Kb downstream the first one, 
spanning from positions chrX:110,695,001–110,845,001, for a overall size of 150 Kb (Fig. 
17). 
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Figure 16. Circle chrX map. WES bioinformatic traces relative to chrX plotted in a circle shape. Starting 
from the middle of the circle we encounter, in order, 4 traces and for each one the red line indicates the mean 
signal. The MASK trace plots signal given from the fraction of N bases present in the 100,000 window is 
measured; peaks that exceed 0,8 value are evidenced (those windows with at least 80% of bases equal to N). 
The BEST-HIT trace plots the signal given by the “mate pairs” best-hit (multiple alignments in the genome); 
the violet band indicate those value in which the signal exceed the mean signal more than a selected 
significant threshold, and for the yellow one the vice versa is true. The UNIQ trace plots coverage signal 
given by the “mate pairs” uniq (reads that align with a unique position in the genome); the violet and yellow 
band have the same meaning of best-hit trace. The CNV trace normalizes signal arising from best-hit + uniq 
trace; regions evidenced in blue should be duplication, whereas orange regions represents deletions. 
 
 
This result seemed to recall the theory of second-site variants that could exert a synergistic 
effect (Girirajan et al., 2012). This second duplication spans a region where it is present 
only one gene whose function it still unknown. 
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Figure 17. WES coverage in Xq22.2 region.  The two yellow highlighted regions present a double coverage 
in respect to the mean coverage of the whole exome, thus indicating that those fragment sequences are present 
in double quantity. 
 
 
Next, we deeply investigated this new finding through CNV-profiling assay and we could 
confirm the second detected duplication (Fig. 18).  
 
 
  
Figure 18. CNV profiling assay applied to the second duplication. Samples 1 and 2 stand for two family 
members each one for each category (normal males, Xq22.2 CNV males, normal females and Xq22.2 CNV 
females).  
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4.3.3  Whole exome sequencing: single nucleotide variant detection and 
validation 
 
 We previously formulated hypothesis about the presence of additional genetic 
determinants, beyond the chrX duplication inherited from the maternal branch, that could 
have been inherited from the paternal branch. To answer this question proband’s exome 
was sequenced and investigated for the presence of single nucleotide variants that could act 
as major susceptibility variants and contribute to the pathogenesis of ICN in this family. 
Data analysis took advantage of QueryOR bioinformatic platform, developed by prof. Valle 
(CRIBI, Padova), that allowed  a good filtering of all the variants identified (Fig. 19). 
 
 
Figure 19. QueryOR example window. 
QueryOr allows the search starting from a 
known gene (General info – gene name) 
or from the type of variant. In particular, 
for example, we can choose  the 
substitution of interest (sense, 
missense,nonsense), a particular genome 
position, the presence or absence in 
dbSNP database, the kind of aminoacid 
change (conservative, moderately 
conservative, radical) and other more 
useful characteristics that can facilitate 
the search. 
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Initially we applied a gene-centered search, that usually starts from the knowledge of genes 
and their function, by selecting 82 genes from the literature for their known relationship 
with nephrolithiasis or other different renal pathologies. In this way we could find out 22 
sense and 42 missense variants.  
As regards sense variants and conservative missense variants,  they have been normally 
believed less impacting on human phenotype, but lately their role in disease pathogenesis 
has been more and more acknowledged for the presence of ESE (Exonic Splicing 
Enhancers)  and ESS (Exonic Splicing Silencers) that, if modified by the presence of a 
sequence variant, can act altering the correct splicing and producing an aberrant mRNA 
(Sterne-Weiler et al., 2011). For these reasons we focused our attention on two sense 
variants lying in NCX1 and NUP62CL genes, because they leapt out from our previous 
investigations, and passed them to the next phase of validation through Sanger sequencing.  
The NCX1 sense variant (rs148215685) was confirmed in heterozygosis in the proband 
and, studying its segregation in the family we could identify the presence in heterozygosis 
in an affected paternal aunt (Fig. 20). Furthermore, NUP62CL sense variant (rs1285590), 
that was also confirmed in homozygosis in the proband and in the other male of the family 
(proband’s cousin) that presented Xq22.2 duplication (Fig. 20). This explain why, 
contrarily to its presence on chromosome X, this variant results effectively in an 
homozygous condition. We found that NUP62CL harbored also a missense variant 
(rs1298577) that, even though it presented a benign/tolerated prediction on protein level, 
because of its presence in the neighborhood of the first sense variant investigated (they both 
presented a MAF value of 0,44), was analyzed for a possible effect on splicing. We used 
ASSEDA software (Automated Splice Site and Exon Definition Analysis, see materials and 
methods)  and it predicted the activation of two criptic acceptor splicing sites of notable 
strenght. Thus, the  potential effect on mRNA splicing need to be clarified. 
For missense variants, basing on our prioritization strategies (see materials and methods), 
we restricted the variant call set to six variants lying in four genes: ATP6V1B1, FGF-23, 
HNF1B, XDH.  Thus, all these variants presented a possibly or probably damaging/ 
deleterious prediction (PolyPhen/SIFT tools) at the protein level, but not always a low 
MAF because, even though it represented a criterion of prioritization, it has been observed 
62 
 
that sometimes it can be not actually discriminating (Cassa et al., 2013). Next, the five 
variants were analyzed in the subsequent phase of molecular validation. 
The ATP6V1B1 gene encodes for an ATPase with a known role in the pathogenesis of 
distal renal tubular acidosis (dRTA), that frequently leads to calcium nephrolithiasis. This 
gene presented two missense variants: one, not known, revealed to be a false positive; 
whereas the other one (rs11681642), that presented a low coverage and quite high 
MAF(=0,39), was confirmed in homozygosis. Next, we studied the segregation in the 
family and we found it in homozygosis in another member of the family (nephew) with  US 
diagnosis of microlithiasis (Fig. 20). In the proband dRTA diagnosis has not been ever 
postulated, but hypocitraturia, the intermediate phenotype that normally accompanies 
tubular acidosis (Escobar et al.,2013), was  always encountered;  the nephew that shared 
this variant also presented hypocitraturia. In other respect,  the variant the we identified and 
confirmed, even with the worst prediction on protein, appears quite frequent in the normal 
population indicating that in some way its potential damaging effect is naturally 
encompassed by other biological mechanisms. This does not change the fact that it could 
have marginal effects on phenotypes like, for example, hypocitraturia. 
The FGF-23 variant, presenting a low coverage, revealed to be a false positive. 
Mutations of HNF1B gene are responsible in heterozygosis in the adult of cystic 
nephropathy sometimes associated with hyperuricemia or hypomagnesemia and 
hypokalemia (Heidet et al., 2010; Faguer et al., 2011). The variant that we identified 
(rs144425230) was known, but so rare that it even not presented a quantifiable MAF, thus 
appearing quite intriguing. This, in spite of his low coverage, was confirmed in 
heterozygosis in the proband. Lately, by studying its segregation in the family, we could 
find it present in heterozygosis in an affected paternal aunt (Fig. 20). However, the proband 
did not present hyperuricemia and hypomagnesemia; but, recently, pre-calyceal renal cysts 
were observed. 
Mutations in XDH gene are normally responsible of xanthinuria, an autosomic recessive 
disease that leads to xanthine stone formation (Gok et al., 2003). We identified two 
variants, rs45624433 and rs17011368 with MAF=0,0005 and MAF=0,017 respectively, that 
were confirmed. The missense variant rs45624433, that had a very bad prediction 
(probably damaging/deleterious) was confirmed in heterozygosis in the proband (Fig. 20). 
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Figure 20.  Genealogic tree where copy-number and single-nucleotide variants identified in the proband are 
illustrated. Their segregation in the case-study family is also shown. 
 
 
 
A segregation study showed that it probably came from maternal branch, because it was 
also present in the mother, the sister and in a maternal uncle (Fig. 20).   
Whereas, missense variant rs17011368, that had a milder prediction (bening/deleterious), 
was confirmed in homozygosis, although it was reported by QueryOR software in the 
heterozygous state (Fig. 20).  By analyzing its segregation in the family, we found that it 
was also inherited from the maternal branch because it appeared present in heterozygosis in 
the mother, the maternal aunt, the sister and his son (proband’s nephew) (Fig. 20). The 
inheritance from the paternal branch was presumed because of the homozygous mutation 
state in the proband. However, in the proband neither xanthine in stone composition nor 
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hypouricemia, intermediate phenotype typical of xanthinuria, were present, but metabolic 
analysis to assess xanthinuria phenotype should be performed. 
Next, we moved to a variant centered search, that is normally more dispersive because it 
does not take origin from a previous knowledge on genes, thus appearing more like 
“looking for a needle in a haystack”.  
Our starting points were: the identification of nonsense variants, because they were 
normally believed as the most damaging; and not known homozygous missense variants, 
for both of their novelty and their presumed major impacting effect because of their 
homozygosis. 
As regards nonsense variants, we could identify 25 genes harboring, of these, only seven 
presented not known or very rare (low MAF values) variants: USP12 and USP29, two 
ubiquitine peptidase; ALK, a tyrosine kinase associated with cancer; SLC5A9, a sodium-
glucose transporter; and FAM108B, ANKR36, ANKR36C, whose function is not well 
known. As primary focus we pointed the attention to the two ubiquitine peptidase, but 
USP29 variant revealed to be a false positive while USP12 is still in phase of validation. 
In the analysis of missense variant we could evidence 35 genes but, after the usual 
prioritization strategy (see materials and methods), only 4 genes deserved further 
investigations: KCNS1, RP1L1,NADK, SHKBP1. We initially passed KCNS1 to the next 
phase of validation because of its possibly significant role: this gene encodes, indeed, for a 
potassium channel that  belongs to  the known family KCN;  to this family belongs the 
most known KCNJ1, with a recognized role in neonatal or late onset Bartter syndrome, 
characterized by hypercalciuria, nephrocalcinosis and kidney stones (Brochard et al., 2009; 
Sharma and Linshaw, 2011). In spite of its appealing significance, we could not confirm by 
Sanger sequencing the two variants identified (both having low coverage). 
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5. CONCLUSIONS 
 
ICN is a complex disease in which environmental, metabolic and genetic factors play 
important and sometimes indiscernible roles, from different perspectives.  
The importance of hereditary factors in ICN has emerged from a number of studies on 
families and twins affected by ICN. Computer programs predicted the best inheritance fit 
with a model of single gene co-dominant model/polygenic model.  
Most candidate gene or association studies have produced, up to date, negative or only 
marginal results, leaving the genetic basis of ICN still an open question. But, genetic 
analysis techniques are rapidly evolving and promise to improve our knowledge of the 
genetic basis of nephrolithiasis and allied disorders. 
Molecular genetics techniques have evolved considerably in the last decade allowing great 
strides forward in the study of complex diseases: the discovery of new genetic variants as 
previously not possible, such as Copy-Number Variants (CNV) thanks to Comparative 
Genomic Hybridization (CGH) technology; and the possibility to sequence entire genomes 
or exomes with a very reduced timeframe and cost, that from the start of a new sequencing 
era with  the completion of Human Genome project in 2001 led to the advent of the 
revolutionary Next Generation Sequencing (NGS) technologies.  
In this study we could take advantage of a case-study remarkably peculiar that permitted us 
to approach ICN genetic basis with these two innovative technologies. This case study was 
extremely peculiar both for its heterogeneous clinical and metabolic manifestations, 
ranging from the exceptionally severe phenotype encountered in the proband to very mild 
phenotypes presented by other family members, both for its clear hereditary component, 
even being a consanguineous family. 
Nevertheless, although dealing with a family in which hereditary factors should play a 
pivotal role, mimicking a mendelian disorder, we could not find any causative mutation of 
the ICN phenotype recurring  in the family. None of the detected variants – either the 
private X-linked CNV, either the damaging missense or sense mutations in ICN significant 
genes - segregated in the family with ICN phenotype. We should remark, indeed, that, 
despite of their consanguineous origin, family members of this family show very 
heterogeneous ICN phenotypes. Thus, this heterogeneity can most likely be the 
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manifestation of an oligogenic or polygenic inheritance.  This is clearly manifested in the 
proband who harbored,  in addition to the CNV with its long range effect on the up-
regulation of NCX1 gene and the NUP62CL rs1298577 variant in homozygosity, also the 
ATP6V1B1 rs11681642 and XDH rs17011368 in the homozygous state and rs45624433 in 
the heterozygous state, as well as  HNF1B rs144425230 in the heterozygous state. All these 
predicted damaging variants in significant genes for the pathogenesis of ICN can act in 
synergy determining the worst ICN phenotype of the proband  and conditioning each other 
regarding their influence on  intermediate phenotype expression. 
None of the variants we identified have been previously found associated with the 
mendelian nephropathies that usually lead to nephrolithiasis, nor they have been previously 
considered as risk factors for nephrolithiasis,  thus they might be considered in future case-
control association studies  as candidate susceptibility variants for idiopathic calcium 
nephrolithiasis. 
However, these technologies need to be critically evaluated in their ability to answer 
specific medical and/or biological questions such as posed by our study. 
From this point of view,  we could definitively prove, that molecular validation of variants 
identified by WES is always necessary for two reasons: the first, of more immediate 
comprehension, is that it helps in the identification of false positives due to low coverage 
regions; the second, less evident but not less important, is that it avoids also false negative 
results because it can prove the reality of some variants that would have normally been 
considered not believable on the basis of their coverage. 
Discovering the genes involved in ICN hopefully will lead to breakthroughs in 
pharmacological targets for treating or preventing these conditions, perhaps to tools for 
diagnosing the risk of developing them, and, finally, but no less importantly, to basic 
science discoveries and a better understanding of renal/intestinal/bone physiology relevant 
to ICN.  
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6. LIST OF ABBREVIATIONS 
 
 
ALK: anaplastic lymphoma kinase 
ANKRD: ankyrin repeat domain  
ANKRD36C : ankyrin repeat domain 36 C 
ATP6V1B1: ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1 
CaR: calcium sensing receptor 
CD-CV: common disease-common variant 
CGH: comparative genomic hybridization 
CLC-5: chloride channel, voltage-sensitive 5 
CLDN2: claudin-2 
CNV: copy-number variants 
CXorf41: chromosome X open readin frame 41 
DGV: database of genomic variants 
DSV: DNA sequence variants 
ESE: exonic spkicing enhancer 
ESS: exonic splicing silencer 
ESWL: extracorporeal shock-wave lithotripsy 
FAM108B: family with sequence similarity 104, member B 
FGF-23: fibroblast grow factor-23 
GPR15: G-protein coupled receptor 15 
GWAS: genome wide association study 
HGP: human genome project 
HNF1B: hepatocyte nuclear grow factor 
ICN: idiopathic calcium nephrolithiasis 
IH: idiopathic hypercalciuria 
KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 
KCNS1: potassium voltage-gated channel, delayed-rectifier, subfamily S, member 1 
LCV: large copy-number variants 
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LMW: low molecular weight 
MAF: minor allele frequency 
MORC4: MORC family CW-type zinc finger 4 
NADK: NAD kinase 
NCX1: Na+/Ca2+ exchanger 1 (SLC8A1) 
NGS: next-generation sequencing 
NUP62CL: nucleoporin 62 C-terminal-like 
PHPT: primary hyperparathyroidism 
PRPS1: phosphoribosyl pyrophosphate synthetase 1 
PTH: parathyroid hormone 
qPCR: quantitative PCR (real-time PCR) 
RBM41: RNA binding motif 41 
RP1L1: retinis pigmentosa 1- like 1 
RV-CD: rare variant-common disease 
SHKB1: SH3KBP1 binding protein 1 
SLC5A9: solute carrier family 5 (sodium/glucose cotransporter), member 9  
SNP: single-nucleotide polymorphisms 
SV: structural variation 
USP12: ubiquitine specific peptidase 12 
USP29: ubiquitine specific peptidase 29 
VDR: vitamin D receptor 
WES: whole exome sequencing 
WGS: whole genome sequencing 
XDH: xanthine dehydrogenase 
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